Apparatus, systems, and methods for aerosolized drug administration

The system addresses challenges in aerosolized drug delivery by using a drug assembly with snap-fit mechanisms and airtight seals to ensure consistent dose uniformity and safety, facilitating deep lung deposition and reducing leakage risks.

JP2026539010APending Publication Date: 2026-11-19GH RES IRELAND LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2026523368
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-18
Filing Date
2024-10-18
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing technologies face challenges in ensuring consistent and safe delivery of aerosolized drugs, particularly for mental and neurological disorders, with issues related to dose uniformity, particle size distribution, ease of use, and risk of leakage.

Method used

A system comprising a drug assembly, aerosol containment device, and vaporizer, which includes a drug cartridge housed in a cartridge housing, connected via a connecting element to a retaining chamber, ensuring secure and controlled delivery of aerosolized drugs through snap-fit mechanisms and airtight seals, allowing for deep lung deposition and minimizing leakage.

Benefits of technology

The system provides consistent dose uniformity, controlled particle size distribution, and safe administration of aerosolized drugs, reducing the risk of leakage and ensuring effective absorption into the bloodstream.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026539010000001_ABST
    Figure 2026539010000001_ABST
Patent Text Reader

Abstract

A system for delivering aerosolized drugs to a patient. The system includes a retaining chamber (108) suitable for containing the drug to be aerosolized, and a connecting element (100) having first and second ends, the second end facing the first end and suitable for connection to the retaining chamber (108). The connecting element further includes one or more mating mechanisms (102, 104, 112, 114, 118) proximal to its first end. The system may also include a mouthpiece (400), a drug assembly (200) including a drug housing (216) and a drug cartridge (300), and a vaporizer (500).
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Patent Application No. 63 / 591,432, filed on October 18, 2023, the entire content of which is hereby incorporated by reference in its entirety into this specification.

[0002] The present disclosure relates generally to devices, systems, and methods for administration of aerosolized medicaments. The present disclosure also generally relates to medicaments for use in the treatment of diseases or disorders, wherein the medicaments are administered by the devices, systems, and methods of the present disclosure. BACKGROUND ART

[0003] Inhalation of aerosolized medicaments is a technique for delivering a medicament to a user. The aerosolized medicament is inhaled into the patient's lungs, which leads to absorption of the medicament into the bloodstream and systemic distribution. SUMMARY OF THE INVENTION

[0004] It will be understood that, for brevity and clarity of illustration, reference numerals may be repeated throughout different drawings to indicate corresponding or similar elements as appropriate. Furthermore, numerous specific details are set forth to provide a thorough understanding of the embodiments described herein. However, it will be apparent to those skilled in the art that the embodiments described herein may be practiced without these specific details. In other instances, methods, procedures, and components have not been described in detail so as not to obscure the relevant features being described. The drawings are not necessarily to scale, and the proportions of certain parts may be exaggerated to better illustrate details and features. This description should not be construed as limiting the scope of the embodiments described herein.

[0005] Several definitions that apply throughout the present disclosure are now set forth.

[0006] The term “coupled” is defined as being connected, whether directly or indirectly through intervening components, and is not necessarily limited to physical connections. Connections may be such that objects are permanently joined or are releasably joined. The term “substantially” is defined as essentially conforming to a particular dimension, shape, or other word that substantially modifies the component so that it does not need to be exact. For example, substantially cylindrical means that an object resembles a cylinder but may have one or more deviations from a true cylinder. The term “includes” means “includes but not necessarily limited to,” and this term specifically indicates an open-ended inclusion or member in a combination, group, set, etc., as described.

[0007] Where used herein, when referring to any numerical value, the term "approximately" means a value that falls within ±10 percent of the stated value.

[0008] In this specification, a range can be expressed as "about" one particular value and / or "about" another particular value. Where such a range is expressed, further aspects include this one particular value and / or this other particular value. Similarly, where a value is expressed as an approximation using the preceding "about," it is understood that this particular value forms further aspects. Furthermore, it is understood that each endpoint of this range is important both in relation to other endpoints and independently of other endpoints. It is also understood that a number of values ​​are disclosed in this specification, and each value is also disclosed in this specification as its particular value "about" in addition to the value itself. For example, if the value "10" is disclosed, then "about 10" is also disclosed. The term "about" is optional when used in relation to a particular value. It is also understood that each group between two particular groups is disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

[0009] The terms “aerosol,” “aerosolized,” or any other variation thereof, are defined as a substance (e.g., a drug) being diffused or suspended in the air, or the conversion of a substance (e.g., a drug) into a form that can be diffused or suspended in the air.

[0010] As used herein, unless otherwise stated, the term “patient” refers to a subject having at least one of the diseases or disorders disclosed herein. The subject is typically human or a non-human animal, such as a mammal. Preferably, the subject is human.

[0011] As used herein, unless otherwise stated, the terms “mental disorder” and “neurological disorder” mean any disorder affecting mood, thought, and behavior, including but not limited to postpartum depression, sleep disorders, major depressive disorder, persistent depressive disorder, bipolar disorder (including bipolar I and bipolar II disorders), anxiety disorders, post-traumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorders, and psychoactive substance abuse. The diagnosis of a patient suffering from a “mental disorder” or “neurological disorder” may be made in accordance with the Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) published by the American Psychiatric Association. Diagnosis may be made by a physician or psychologist. Generally, it is not sufficient for a human subject to believe that they suffer from one of the disorders.

[0012] As used herein, unless otherwise specified, the terms “to treat” and “to cure” include the management and care of a patient for the purpose of combating a disease or disorder, and include administering drugs in accordance with this application (e.g., by the methods and systems disclosed herein), alleviating signs and / or symptoms, or eliminating a disease or disorder.

[0013] The problems addressed by the disclosed subject matter included finding solutions to ensure that active pharmaceutical ingredients (APIs) or drugs are appropriately administered to patients who need them. The disclosed apparatus, systems, and methods provide physicians and other aerosol handlers with greater consistency in delivery dose uniformity, particle size distribution, and ease of use. For example, the apparatus, systems, and methods provided herein enable the safe and effective administration of aerosols that may contain aerosolized drugs. Furthermore, the disclosed apparatus, systems, and methods enable the production of aerosols with properties (e.g., particle size distribution) suitable for deep lung deposition. In addition, the disclosed apparatus, systems, and methods enable the safe production and administration of psychoactive compounds, thereby enabling the production and administration of aerosols while reducing the risk of leakage and inadvertent exposure.

[0014] This application provides a method for administering a drug (e.g., 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, etc.) by inhaling an aerosolized drug into the lungs, thereby ultimately allowing the drug to be absorbed into the bloodstream and distributed throughout the body. Aerosolized drugs can be produced by exposing a drug-containing material to high temperatures. A drug can also be heated to a vapor and then cooled to condense it into an aerosolized drug. Aerosolized drugs can be delivered with a certain amount of air.

[0015] Based on their pharmacological activity, drugs have potential medical applications. For example, use in human clinical trials and in approved medical products for patient treatment requires the administration of highly purified drugs.

[0016] This application provides a drug (e.g., 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, etc.) for use as a pharmaceutical, the drug being administered to a patient in need by the method disclosed herein.

[0017] This application provides a drug (e.g., 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, etc.) for use in the treatment of a disease or disorder, the treatment comprising administering the drug to a patient in need of the drug, the drug being administered by the method disclosed herein.

[0018] This application provides the use of a drug (e.g., 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, etc.) for the manufacture of a pharmaceutical product for the treatment of a disease or disorder, wherein the treatment comprises administering the drug to a patient in need of the drug, and the drug is administered by the method disclosed herein.

[0019] This application provides a drug (e.g., 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, etc.) for use as a pharmaceutical, which is administered to a patient in need by a system disclosed herein.

[0020] This application provides a drug (e.g., 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, etc.) for use in the treatment of a disease or disorder, the treatment comprising administering the drug to a patient in need of the drug, the drug being administered by a system disclosed herein.

[0021] This application provides the use of a drug (e.g., 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, etc.) for manufacturing a pharmaceutical product for the treatment of a disease or disorder, the treatment comprising administering the drug to a patient in need of the drug, the drug being administered by a system disclosed herein.

[0022] This application provides a drug (e.g., 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, etc.) for use as a pharmaceutical, the drug being contained within a drug assembly disclosed herein.

[0023] This application provides a drug (e.g., 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, etc.) for use in the treatment of a disease or disorder, the drug being contained within a drug assembly disclosed herein.

[0024] This application provides the use of a drug (e.g., 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, etc.) for the manufacture of a pharmaceutical product for the treatment of a disease or disorder, wherein the drug is contained within a drug assembly disclosed herein.

[0025] Examples of diseases or disorders that can be treated by the present disclosure include postpartum depression, sleep disorders, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorders, post-traumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorders, psychoactive substance abuse, epilepsy, chemotherapy-induced nausea, acute pain, chronic pain, phantom limb pain, migraine, multiple sclerosis, multiple sclerosis seizures, schizophrenia, insomnia, rheumatoid arthritis, psychosis, HIV-induced anorexia, sleep apnea, alcohol use disorder, suicidal ideation, psychoactive substance use disorder, smoking cessation, Parkinson's disease, dementia, pleuropneumonia, parasitic pathologies, Pneumocystis pneumonia, HIV-associated dementia, cough, diarrhea, nausea, opioid abuse, seizures and shortness of breath. In at least one example, diseases or disorders that can be treated by the present disclosure include postpartum depression, sleep disorders, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorders, post-traumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorders, psychoactive substance abuse, epilepsy, acute pain, chronic pain, phantom limb pain, migraine, multiple sclerosis, schizophrenia, insomnia, rheumatoid arthritis, psychosis, sleep apnea, suicidal ideation, Parkinson's disease, dementia, pleuropneumonia, parasitic pathologies, Pneumocystis pneumonia, diarrhea, and nausea.

[0026] The present application provides medicaments (e.g., 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, etc.) for use in the treatment of psychiatric disorders or nervous system disorders, comprising administering the medicament to a patient in need of the medicament, wherein the medicament is administered by the methods disclosed herein.

[0027] The present application also provides medicaments (e.g., 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, etc.) for use in the treatment of psychiatric disorders or nervous system disorders, wherein the medicament is administered by the systems disclosed herein.

[0028] The present application also provides a medicament (e.g., 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, etc.) for use in the treatment of psychiatric disorders or nervous system disorders, comprising administering the medicament to a patient in need of the medicament, wherein the medicament is contained within the medicament assembly disclosed herein.

[0029] Examples of psychiatric disorders or nervous system disorders treatable by the present disclosure include postpartum depression, sleep disorders, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorders, post-traumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorders, and psychoactive substance abuse. In a preferred example, the psychiatric disorder or nervous system disorder is major depressive disorder.

[0030] The present application also provides a medicament (e.g., 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, etc.) for use in the treatment of treatment-resistant forms of psychiatric disorders or nervous system disorders, comprising administering the medicament to a patient in need of the medicament, wherein the medicament is administered by the methods disclosed herein.

[0031] The present application also provides a medicament (e.g., 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, etc.) for use in the treatment of treatment-resistant forms of psychiatric disorders or nervous system disorders, comprising administering the medicament to a patient in need of the medicament, wherein the medicament is administered by the systems disclosed herein.

[0032] The present application also provides a medicament (e.g., 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, etc.) for use in the treatment of treatment-resistant forms of psychiatric disorders or nervous system disorders, wherein the medicament is contained within the medicament assembly disclosed herein.

[0033] Unless otherwise stated, drugs are administered as aerosolized drugs. By administering aerosolized drugs to a patient by the methods and systems disclosed herein, or as part of the drug assemblies disclosed herein, absorption of the drug into the patient's bloodstream can be achieved, and systemic distribution can be accomplished.

[0034] Drugs can be pre-packaged for transport and storage. Holding the drug in a drug cartridge before packaging, transport, and / or storage ensures the correct dosage and administration of the drug via the drug cartridge. For example, the drug cartridge may be held in a drug cartridge housing or integrated with the drug cartridge housing. The drug cartridge and drug cartridge housing together may be called a drug assembly. However, the drug assembly should be capable of holding the drug without leakage and ensuring that the correct dosage of the drug is supplied. The drug assembly should also be able to deliver the desired thermal energy to the held drug, allowing it to vaporize efficiently. Furthermore, the drug assembly should also have sufficient porosity to allow air to flow through it, facilitating and releasing the drug.

[0035] In at least one example, a drug cartridge may be held in a drug cartridge housing during storage, transport, and use. When in use, the drug cartridge housing that holds the drug cartridge may be used with a vaporizer without the need to remove the drug cartridge. Holding the drug cartridge in a housing may make the cartridge easier to handle, for example, and / or increase the cartridge's resistance to tampering.

[0036] Disclosed herein is a system for delivering aerosols to patients who require them. The system may include a drug assembly, an aerosol containment device, a mouthpiece, and a vaporizer.

[0037] Further features of this disclosure will become apparent to those skilled in the art in which this disclosure relates by reading the following specification with reference to the accompanying drawings. [Brief explanation of the drawing]

[0038] [Figure 1A] This is an isometric view of a connecting element and a retaining chamber according to at least one example of the present disclosure. [Figure 1B] This is a front view of the connecting element and the retaining chamber. [Figure 2] This is a bottom view of the connecting element and the retaining chamber. [Figure 3] This is an isometric view of a drug assembly. [Figure 4] This is a front view of a drug assembly. [Figure 5] This is a left-side view of the drug assembly. [Figure 6] This is a right-side view of the drug assembly. [Figure 7] This is an isometric view of the bottom of the drug assembly. [Figure 8] This is an isometric view of the mouthpiece. [Figure 9] This is a front view of the mouthpiece. [Figure 10] This is a rear view of the mouthpiece. [Figure 11] This is an isometric view of the vaporizer. [Figure 12] This is a front view of the vaporizer. [Figure 13] This is a rear view of the vaporizer. [Figure 14] This is a flowchart of a method used in one example. [Modes for carrying out the invention]

[0039] Figures 1A-2 show an example of an aerosol containment device. The aerosol containment device may include a connecting element 100 connected to a holding chamber 108. The connecting element 100 may include one or more mating mechanisms. As shown in Figures 1A-2, one or more mating mechanisms may include a first locking clip 114(a) (e.g., a snap arm), a first release tab 102(a), a second locking clip 114(b) (e.g., a snap arm), and a second release tab 102(b). One or more mating mechanisms may further include four slots 112(a), 112(b), 112(c), 112(d). Each of the four slots 112(a), 112(b), 112(c), and 112(d) can be positioned adjacent to either side of the first locking clip 114(a) and the first release tab 102(a), and the second locking clip 114(b) and the second release tab 102(b).

[0040] The locking clips 114(a) and 114(b) can be received inside the respective slots of the drug assembly. The locking clips 114(a) and 114(b) can be locked in place within their respective slots, thereby creating a secure connection between the connecting element 100 and the drug assembly. The release tabs 102(a) and 102(b) can be compressed to release (i.e., unlock) the locking clips 114(a) and 114(b) from their respective slots. The lower part of the release tabs 102(a) and 102(b) may have grooves that can be compressed to release the locking clips 114(a) and 114(b) from their respective slots. More than two release tabs, locking clips, and slots can be used. For example, the connecting element 100 may include 3, 4, 5, 6, 7, 8, 9, 10, or even more release tabs and locking clips configured to be removably coupled into the respective slots of the drug cartridge housing and / or mouthpiece. The connecting element 100 can be removably coupled to the drug assembly using other mating mechanisms. For example, other snap-fit ​​mechanisms, groove and projection (e.g., rotation lock) mechanisms, latches, magnetic connections, or other mating mechanisms known in the art can be used. One or more mating mechanisms of the connecting element 100 can provide a retaining function between the connecting element 100 and the drug assembly and / or mouthpiece, thereby creating and maintaining a seal between the internal channel of the connecting element 100 and the drug assembly and / or mouthpiece.

[0041] One or more mating mechanisms of the connecting element 100 may further include two retaining tabs 104(a), 104(b). The retaining tabs 104(a), 104(b) may be configured to mate through a hole in the drug assembly and to make direct contact with the drug assembly port of the vaporizer. When the drug assembly is removably coupled to the connecting element 100, the drug assembly and the connecting element 100 may be removably coupled to the drug assembly port of the vaporizer. Both the drug assembly and the connecting element 100 may have components configured to directly couple to the drug assembly port of the vaporizer. The two retaining tabs 104(a), 104(b) of the connecting element 100 pass through a hole in the drug assembly and contact the corresponding surface of the drug assembly port. The two retaining tabs 104(a), 104(b) may be triangular. The two retaining tabs 104(a) and 104(b) may be of other shapes that are operable to prevent rotation together with corresponding tabs on corresponding faces of the drug assembly port of the vaporizer. When the drug assembly and connecting element 100 rotate to removably connect to the drug assembly port, the two retaining tabs 104(a) and 104(b) can slide over corresponding tabs on faces of the drug assembly port, thereby engaging into place and preventing the drug assembly and connecting element 100 from rotating in one direction. The two retaining tabs 104(a) and 104(b) perform a retaining function, thereby preventing the drug assembly from being removed from the drug assembly port of the vaporizer by preventing it from rotating in the reverse direction (for example, in the opposite direction of rotation to connect the drug assembly and connecting element 100 to the vaporizer port). The connecting element 100 must first be disconnected from the drug assembly by compressing the release tabs 102(a) and 102(b) so that the drug assembly can be removed from the drug assembly port by the two retaining tabs 104(a) and 104(b).

[0042] The retaining tabs 104(a) and 104(b) are configured to lock the rotation of the drug assembly and the connecting element 100 into the drug assembly port of the vaporizer, but do not prevent the removal of the connecting element 100 in a translational manner (e.g., removal perpendicular to the axis of rotation of the drug assembly port). The projection of the drug assembly described herein prevents the drug assembly from being removed translationally from the groove of the drug assembly port (e.g., removal perpendicular to the drug assembly port). Therefore, the connecting element 100 must be removed from the drug assembly port of the vaporizer before the drug assembly is removed from the drug assembly port.

[0043] One or more mating mechanisms of the connecting element 100 may further include two additional slots 118(a), 118(b). Slots 118(a), 118(b) may be configured to receive the tab of the mouthpiece. The connecting element 100 can be removably coupled to the mouthpiece using other mating mechanisms. For example, other snap-fit ​​mechanisms, groove and projection (e.g., rotation lock) mechanisms, latches, magnetic connections, or other mating mechanisms known in the art may be used. When slots 118(a), 118(b) are removably coupled to the tab of the mouthpiece, a retaining function can be provided between the connecting element 100 and the mouthpiece, preventing fluid leakage between the connected internal channels of the connecting element 100 and the mouthpiece.

[0044] The connecting element 100 may have a slot 112(a) adjacent to the release tab 102(b) and the locking clip 114(b). The connecting element 100 may have another slot 112(d) adjacent to the opposite side of the release tab 102(b) and the locking clip 114(b), as shown, for example, in Figure 2. Similarly, slots 112(b) and 112(c) may be adjacent to each side of the release tab 102(a) and the locking lip 114(a). Slots 112(a), 112(b), 112(c), and 112(d) may be configured to receive their respective projections from the mouthpiece, thereby guiding the mating mechanism of the connecting element 100 to removably couple with the mating mechanism of the mouthpiece. The locking clips 114(a) and 114(b) may further provide a guiding function by mating between the projections of the mouthpiece. The locking clips 114(a) and 114(b) can ensure that the mouthpiece and the connecting element 100 can only move relative to each other along one axis. The slots 118(a) and 118(b) and the corresponding tabs on the mouthpiece can provide a permanent or nearly permanent connection (e.g., an irreversible connection) between the connecting element 100 and the mouthpiece. The retaining tabs 104(a) and 104(b) can be bent radially outward to allow the mouthpiece tabs to connect to the slots 118(a) and 118(b). The retaining tabs 104(a) and 104(b) can then fix the mouthpiece tabs in place within the slots 118(a) and 118(b). The slots 118(a), 118(b), 112(a), 112(b), 112(c), and 112(d) can be formed on the outside of the connecting element 100.

[0045] The connecting element 100 can be connected to the retaining chamber 108. The retaining chamber 108 can be configured to receive and contain an aerosolized drug. The connecting element 100 and the retaining chamber 108 can be connected via a permanent seal. The permanent seal may be a ring 106. The ring 106 may be a silicone gasket or another similar type of ring capable of sealing the retaining chamber 108 and the connecting element 100. The connecting element 100 can be connected to and sealed to the retaining chamber 108 using a snap-fit ​​connection or other connecting mechanism. The connecting element 100 can be directly connected to the retaining chamber 108 using the material of the retaining chamber 108 which has been sealed to the connecting element 100 by soldering, welding, or other means.

[0046] The retaining chamber 108 can be manufactured in a rolled-up configuration to facilitate transport and can be unrolled before use. The retaining chamber 108 may be collapsible (e.g., foldable, rolled up, etc.) to facilitate transport. The retaining chamber 108 may have a volume of about 0.5 liters (L) to about 1 L, about 1 L to about 2 L, about 2 L to about 3 L, about 3 L to about 4 L, about 4 L to about 5 L, or more. The retaining chamber 108 may have a coating on its inner surface configured to prevent the adhesion of aerosolized drugs. The retaining chamber 108 can be made of upright material, thus allowing the entire volume of the retaining chamber 108 to be filled without any resistance from the retaining chamber walls. For example, the retaining chamber 108 can be made of upright material, thus allowing the entire volume of the retaining chamber 108 to be filled without any interference from the retaining chamber walls. Furthermore, the retaining chamber 108 may be configured to stand upright to facilitate the formation of aerosolized drugs upon entry into the retaining chamber and to minimize the impact of the aerosolized drugs on the retaining chamber walls. The retaining chamber 108 may be made of a rigid material that does not curl. The retaining chamber 108 may include an outer rigid material configured to stand upright and an inner flexible material configured to contain the aerosolized drugs. The outer rigid material may surround the inner flexible material or be open. The inner surface of the retaining chamber 108 may be antistatic. The inner surface of the retaining chamber 108 may have an inlet (e.g., coupled / sealed to a connecting element) configured to minimize the adhesion of the aerosolized drugs.

[0047] As shown in Figure 1B, the retaining chamber 108 may include one or more materials. The retaining chamber 108 may include one or more transparent portions 124 and one or more opaque portions 122. The one or more transparent portions 124 may be fully transparent or partially transparent. The one or more transparent portions 124 may allow a user to see the contents inside the retaining chamber 108. For example, a user may assess the filling level of the retaining chamber 108 by looking at the contents inside the retaining chamber 108 through the one or more transparent portions 124. The one or more transparent portions 124 may allow a user to assess whether the retaining chamber 108 is full or empty. The entire retaining chamber 108 may be formed of a transparent or partially transparent material.

[0048] The connecting element 100 may have a channel 110 (e.g., an internal fluid channel). The channel 110 can be in fluid communication with the retaining chamber 108, thereby providing a fluid channel for fluid to flow from the connecting element 100 to the retaining chamber 108. When the connecting element is connected to the mouthpiece and / or drug assembly, the channel 110 can create a sealed fluid channel between the mouthpiece and / or drug cartridge housing and the retaining chamber 108.

[0049] The connecting element 100 can be made of metal, plastic, or other material. The retaining chamber 108 can be made of plastic or another flexible or rigid material that generates a sealed amount of fluid. The connecting element 100 and the retaining chamber 108 may be heat resistant. The connecting element 100 and the retaining chamber 108 can be formed of a material that is resistant to melting or generating toxic fumes when in close proximity to the vaporizer, thereby preventing the generation and addition of undesirable particles to the aerosolized drug in doses administered to the patient.

[0050] The connecting element 100 may have a valve in the channel 110. The valve in the channel 110 may have an open state and a closed state. In the open state, the valve may allow fluid to flow through the channel 110 into the retaining chamber 108 or out through a mouthpiece attached to the end of the connecting element 100 on the opposite side of the retaining chamber 108. In the closed state, the valve may prevent fluid from flowing into or out of the retaining chamber 108. In the closed state, the valve may form a seal (for example, by contacting the side wall of the channel 110). In this way, the valve may retain any fluid in the retaining chamber 108 and prevent any fluid from entering the retaining chamber 108.

[0051] The valve can spontaneously close, meaning that the valve is closed when no force is applied. When the connecting element 100 is connected to the drug assembly, the valve may be subjected to force from the drug assembly. The force applied to the valve can set the valve in the open position (for example, allowing fluid to flow through the connecting element 100 into the holding chamber 108). In this way, when the drug is being transferred to the aerosolized drug in the holding chamber 108, the valve may be open (for example, due to the force applied by the drug assembly). The connection between the drug assembly and the connecting element 100 can automatically set the valve in the open position. When the mouthpiece is attached to the connecting element 100, the valve can be set in the open position by applying force (for example, translating the mouthpiece inward toward the connecting element 100). The valve can be moved into the open position by pushing the mouthpiece toward the connecting element when the patient is ready to inhale the aerosolized drug. The connection between the mouthpiece, the drug assembly, and the connecting element is described further herein.

[0052] The valve in the channel 110 of the connecting element may have a link mechanism arm 120. The link mechanism arm 120 may have a spring. A force applied from either the drug assembly or the mouthpiece may be applied to the link mechanism arm 120. When a force is applied to the link mechanism arm 120, the link mechanism arm 120 can move the valve to the open position. When a force is applied by the drug assembly, the shape of the drug assembly always overcomes the spring force while the drug assembly is attached to the connecting element (for example, the drug assembly is configured such that once connected, the force against the spring is overcome by the connecting force of the drug assembly). When a force is applied by the mouthpiece, the spring may generate an opposing force on the mouthpiece, so a force greater than the force applied by the spring must be applied to the mouthpiece to move the valve to the open position.

[0053] As shown in Figure 3, the system may include a drug assembly 200 which includes a drug cartridge housing 216 and a drug cartridge 300. The drug assembly 200 may have a channel 204 and one or more mating mechanisms configured to be removably coupled to various components of the system. The drug assembly 200 may have a first housing mating mechanism, a second housing mating mechanism, and a third housing mating mechanism. The first housing mating mechanism may be a first slot 202(a) and a second slot 202(b). The first slot 202(a) and the second slot 202(b) may be located on opposite sides of the drug assembly 200. The slots 202(a) and 202(b) may be configured to be removably coupled to the locking clips 114(a) and 114(b) of the connecting element 100. The first housing mating mechanism may be another type of mating mechanism configured to be removably coupled to one or more mating mechanisms of the connecting element 100. The first housing mating mechanism may include other snap-fit ​​mechanisms, groove and projection (e.g., rotation lock) mechanisms, latches, magnetic connections, or other mating mechanisms known in the art. The connecting element 100 can be secured to the drug assembly 200 using any type of opposing mating mechanism.

[0054] As shown in Figure 4, the drug assembly 200 may have two guides 206(a) and 206(b) on the first slot 202(a) and the second slot 202(b), respectively. The guides 206(a) and 206(b) can be used to align the first slot 202(a) and the second slot 202(b) with the locking clips 114(a) and 114(b) of the connecting element 100.

[0055] The drug assembly 200 can automatically set the valve of the connecting element 100 in the open position when the drug assembly 200 is detachably connected to the connecting element. The drug assembly 200 may have one or more crosshair posts 214(a), 214(b) that are operable to apply force to the link mechanism arm 120 of the drug assembly. Either of the crosshair posts 214(a), 214(b) can communicate with the link mechanism arm, depending on the orientation of the connection. The crosshair posts are long enough to apply a constant force to the link mechanism arm when the drug assembly 200 is detachably connected to the connecting element 100, thereby keeping the valve open. When the drug assembly 200 is disconnected from the connecting element, the force from either of the crosshair posts 214(a), 214(b) is removed, and the valve transitions to the closed position.

[0056] The drug assembly 200 may include a channel 204. The channel 204 may be long enough to activate (e.g., apply force) a valve in the channel 110 of the connecting element 100 when the drug assembly 200 is removably connected to the connecting element 100. In this way, a fluid flow can be provided between the drug assembly 200 and the retaining chamber 108.

[0057] The channel 204 of the drug assembly 200 and the channel 110 of the connecting element 100 can be configured (e.g., sized) to create an airtight seal so that the fluid supplied to the drug assembly 200 cannot escape from the drug assembly channel 204, the connecting element channel 110, or the retaining chamber 108. The drug assembly channel 204 and the connecting element channel 110 may have an airtight seal provided by a compliance seal and / or O-ring configured to seal the channel when connected.

[0058] As shown in Figures 4-7, the drug cartridge 300 can be connected to the drug cartridge housing 216, thereby forming a drug assembly 200. The drug cartridge 300 can be integrated with the drug cartridge housing 216 (e.g., irreversibly coupled). The drug cartridge 300 and the drug cartridge housing 216 can be manufactured as a single component (e.g., formed from a single part). The drug cartridge 300 can be coupled to the drug cartridge housing 216 via a second housing fitting mechanism.

[0059] As shown in Figure 7, the second housing fitting mechanism may have three tabs 208(a), 208(b), 208(c) and a retaining member 212. The drug cartridge 300 may have a flange located above the retaining member 212 (for example, proximal to the channel 204). The retaining member 212 can be held in place by the tabs 208(a), 208(b), 208(c). The drug cartridge 300 can be inserted into the drug cartridge housing 216. The retaining member 212 can then be inserted below the flange of the drug cartridge 300. The retaining member 212 can then be locked in place by the tabs 208(a), 208(b), 208(c). In this way, the drug cartridge 300 can be held in place inside the drug assembly 200. The drug cartridge 300 can be held in the drug cartridge housing 216 using other fitting mechanisms and configurations. The second housing mechanism may be another snap-fit ​​mechanism, groove and projection (e.g., rotation lock) mechanism, latch, magnetic connection, or other mating mechanism known in the art. The drug cartridge 300 can be secured to the drug cartridge housing 216 using any mating mechanism. The drug cartridge 300 can only be inserted into the drug cartridge housing 216 and cannot be disconnected. The drug cartridge 300 is permanently connected to the drug cartridge housing 216. Permanently connecting the drug cartridge 300 to the drug cartridge housing 216 prevents misuse of the drug. Furthermore, since drug administration can be performed at the manufacturing facility rather than by the end user, proper drug administration can be ensured. The configuration of the drug cartridge housing 216 and drug cartridge 300, which are permanently (e.g., irreversibly) connected, improves operability and makes it more user-friendly by minimizing the number of assembly steps.

[0060] The drug assembly 200 may have a third housing mating mechanism. The third housing mating mechanism may be a plurality of projections configured to lock or guide the movement of the vaporizer's drug assembly port into the groove. The third housing mating mechanism may consist of two projections 210(a), 210(b) (e.g., a port mating mechanism). The two projections 210(a), 210(b) may be configured to fit into the groove of the vaporizer's drug assembly port. The drug assembly 200 can be rotated, thereby rotating the projections 210(a), 210(b) in the groove to guide the retaining tabs 104(a), 104(b) of the connecting element 100 to lock into place with the corresponding tabs of the drug assembly port. The two projections 210(a), 210(b) may be locked into place inside the drug assembly port using a snap-fit, latch, or other similar mating mechanism. A third housing mating mechanism may be any other type of mating mechanism described herein that is operable to secure the drug assembly 200 to the drug assembly port of the vaporizer. As described above, the retaining tabs 104(a), 104(b) can lock the coupled connecting element 100 and the drug assembly 200 within the drug assembly port and prevent reverse rotation (for example, rotating the drug assembly 200 and the connecting element 100 in the opposite direction to the rotation that locked the drug assembly 200 and the connecting element 100 in place), thereby requiring the removal of the connecting element 100 before the drug assembly 200 can be removed from the drug assembly port of the vaporizer.

[0061] The drug cartridge housing 216 can be made from a heat-resistant material, meaning that it will not melt or leach toxic particles when heated, making it suitable for handling. The drug cartridge housing 216 can be made from metal, plastic, or other suitable material.

[0062] The drug cartridge 300 may be operable to hold the drug in a solid form. The drug may be 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), cannabinoids, tetrahydrocannabinol, enteractogen 3,4-methylenedioxymethamphetamine, ketamine, lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, phenylalkylamine mescaline, other tryptamines, other ergolines, other serotonergic compounds, second-generation psychedelics, nicotine, pentamidine, and / or opioids such as fentanyl, morphine, naloxone, or other drugs designed to be administered in aerosolized form. The drugs may be opioids such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), cannabinoids, tetrahydrocannabinol, the enterogen 3,4-methylenedioxymethamphetamine, ketamine, lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, phenylalkylamine mescaline, nicotine, pentamidine, and / or fentanyl, morphine, naloxone. Preferably, the drug is 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) (i.e., mebfotenin) or a pharmaceutically acceptable salt thereof. In particular, the drug is 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) (i.e., mebfotenin) free base. The drug may be hydrophilic or hydrophobic. The aerosolization process may differ depending on whether the drug is hydrophilic or hydrophobic. The drug may have a melting point of about 50°C to about 80°C. The drug may have a melting point of about 67.5°C. Preferably, the drug is 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) (i.e., mebfotenin) free base, which has a melting point of about 67.5°C.Other drugs with different melting points may be used. The drug could be the HBr salt of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) (i.e., mebufotenin), which has a melting point of about 173°C. In another example, other pharmaceutically acceptable salts with melting points between about 100°C and about 250°C may be used.

[0063] Figures 8 to 10 show the mouthpiece 400. The mouthpiece 400 may be configured to connect to the connecting element 100 when the retaining chamber 108 is filled with a dose of aerosolized drug. The mouthpiece 400 is configured to allow the patient to inhale the aerosolized dose from the retaining chamber 108. The mouthpiece 400 may have one or more mating mechanisms configured to removably connect to one or more mating mechanisms of the connecting element 100. The mouthpiece mating mechanism may include at least one projection and at least one tab. One or more mating mechanisms of the mouthpiece 400 may consist of four projections 402(a), 402(b), 402(c), 402(d) and two tabs 404(a), 404(b). The mouthpiece 400 may further include a front plate 410, an opening 408, a lip 412, and a channel 406 that is in fluid communication with the opening 408.

[0064] The four protrusions 402(a), 402(b), 402(c), and 402(d) may be operable to be inserted into the slots 112(a), 112(b), 112(c), and 112(d) of the connecting element 100. By inserting the four protrusions 402(a), 402(b), 402(c), and 402(d) into the slots 112(a), 112(b), 112(c), and 112(d) of the connecting element 100, the tabs 404(a) and 404(b) of the mouthpiece 400 can be aligned with the slots 118(a) and 118(b) of the connecting element 100. The tabs 404(a) and 404(b) of the mouthpiece 400 can be locked into the slots 118(a) and 118(b) of the connecting element 100, thereby allowing the mouthpiece 400 to be coupled to the connecting element 100. The retaining tabs 104(a) and 104(b) can be bent radially outward to allow the tabs 404(a) and 404(b) of the mouthpiece 400 to slide into the slots 118(a) and 118(b). The tabs 104(a) and 104(b) can then spring back into place, preventing them from being removed from the slots 118(a) and 118(b) of the connecting element 100. Furthermore, the mouthpiece 400 can be coupled to the connecting element 100 using other mating mechanisms described herein. The mating mechanism can create a permanent or nearly permanent connection between the mouthpiece 400 and the connecting element 100. In some examples, once the mouthpiece 400 is coupled to the connecting element 100, it cannot be removed from the connecting element 100.

[0065] The mouthpiece 400 may have a channel 406, an opening 408, and a front plate 410. The channel 406 of the mouthpiece 400 can form an airtight seal together with the channel 110 of the connecting element, thereby preventing fluid from entering the external environment. The airtight seal between the channel 406 of the mouthpiece 400 and the channel 110 of the connecting element 100 may be provided by a compliance seal and / or one or more O-rings. The one or more O-rings may include one or more parylene-coated O-rings. The one or more O-rings may include a single O-ring or multiple O-rings. The one or more O-rings may surround the periphery of the channel 110 and / or channel 406. The mouthpiece 400 may have one or more struts 414(a), 414(b) configured to apply force to the link mechanism arm 120 of the connecting element. The patient applies force to the mouthpiece (e.g., the front plate 410), thereby allowing the struts 414(a) and 414(b) to apply force to the link mechanism arm 120. When force is applied to the link mechanism arm 120, it causes the valve of the connecting element 100 to move to the open position. The struts 414(a) and 414(b) can be sized such that the mouthpiece 400 must be translated inward toward the connecting element of the struts 414(a) and 414(b) in order to apply force to the link mechanism arm 120. The link mechanism arm 120 may have a spring that returns the valve to the closed position when the force from the patient is removed. When the valve is open, the patient can inhale the aerosolized drug from the holding chamber 108 through the opening 408 of the mouthpiece 400. Other configurations of the mouthpiece 400 can be used to apply contact and force to the link mechanism arm. For example, the lip 412 may have one or more struts or other projections that contact and apply force to the link mechanism arm 120. One or more parylene-coated O-rings may be configured to reduce the force that activates the mouthpiece, ensuring that the retaining chamber 108 is reliably sealed (for example, ensuring that the valve is closed) when no force is supplied to activate the mouthpiece.

[0066] The mouthpiece 400 may have additional struts 418(a), 418(b), 418(c), 418(d), 418(e), and 418(f). In a similar manner to struts 414(a) and 414(b), the additional struts 418(a), 418(b), 418(c), 418(d), 418(e), and 418(f) may also be used to contact the link mechanism arm 120 of the connecting element.

[0067] The supports 414(a), 414(b), 418(a), 418(b), 418(c), 418(d), 418(e), and 418(f) of the mouthpiece 400 can be sized so that the valve of the channel 110 of the connecting element 100 does not automatically activate when the mouthpiece 400 is connected to the connecting element 100. In this way, premature leakage of the aerosolized drug from the retaining chamber 108 can be prevented. The patient can apply force to the opening 408 of the mouthpiece 400 or the front plate 410 to push the channel 406 of the mouthpiece 400 inward toward the connecting element 100. When the patient applies force, the valve of the channel 110 of the connecting element 100 can be activated to the open position, allowing the patient to inhale the aerosolized drug from the retaining chamber 108 through the opening 408.

[0068] The mouthpiece 400 can be integrated with the connecting element 100. For example, the mouthpiece can be integrated with the end of the connecting element 100 on the opposite side of the retaining chamber 108.

[0069] The mouthpiece 400 may include one or more vents to allow the patient to inhale a volume greater than the volume in the retaining chamber 108. The mouthpiece 400 may include four vents 416(a), 416(b), 416(c), and 416(d). Vents 416(a), 416(b), 416(c), and 416(d) may allow the patient to perform “chaser” breathing, meaning that breathing continues beyond the volume held in the retaining chamber 108. Vents 416(a), 416(b), 416(c), and 416(d) may also allow the patient to inhale air from outside the retaining chamber 108 after the entire volume of the retaining chamber 108 has been inhaled. Chaser breathing may allow for deeper lung inhalation. Furthermore, chaser breathing can prevent the patient from experiencing a feeling of complete blockage when the entire volume of the retaining chamber 108 has been inhaled.

[0070] As shown in Figures 11-13, the system may include a vaporizer 500. The vaporizer 500 may include a drug assembly port 504, a heating element, and a display screen 502. The drug assembly port 504 may be configured to receive (e.g., dock) a drug assembly 200. The drug assembly port 504 may include a groove 506 that can be operated to receive two projections 210(a) and 210(b) of the drug assembly 200. The two projections 210(a) and 210(b) of the drug assembly port 200 can be inserted into the groove 506 of the drug assembly port 504. The drug assembly 200 may then be rotated so that the two projections 210(a) and 210(b) rotate in the groove 506 of the drug assembly port 504. The drug assembly 200, to which the connecting element 100 is attached, can be rotated until the retaining tabs 104(a), 104(b) of the connecting element 100 snap or mat with the corresponding tabs 514(a), 514(b) of the drug assembly port into place. In another example, two projections 210(a), 210(b) can be locked into place within the groove 506 using a mating mechanism such as a snap-fit ​​or other locking mechanism. In this way, the drug assembly 200 can be removably coupled to the vaporizer 500. The drug assembly 200, connecting element 100, and vaporizer 500 can be coupled in such a way that the internal components of the drug assembly 200, connecting element 100, retaining chamber 108, and vaporizer 500 are sealed from the external environment, thereby preventing any leakage of fluid to the external environment.

[0071] The release tabs 102(a) and 102(b) of the connecting element 100 can be compressed to release the locking clips 114(a) and 114(b) from the slots 202(a) and 202(b) of the drug assembly 200. The ridges of the release tabs 102(a) and 102(b) can be compressed while the drug assembly 200 is coupled to the drug assembly port 504 of the vaporizer 500 to discouple the connecting element 100 and the retaining chamber 108 from the drug assembly 200. The connecting element 100 can also be directly and detachably coupled to the vaporizer 500 while the connecting element 100 is also detachably coupled to the drug assembly 200 using other fitting mechanisms described herein.

[0072] The vaporizer 500 may include a power port 512. The power port 512 may be configured to receive power from a power source. The vaporizer 500 may be powered by a battery or any other power source known in the art. The vaporizer 500 may include an on / off switch 508. The on / off switch 508 may be configured to turn the vaporizer 500 on or off.

[0073] The vaporizer 500 may further include a fan located inside the vaporizer 500. The fan can cool the components of the vaporizer 500, thereby preventing the vaporizer 500 from becoming excessively hot. The fan may be in fluid communication with a plurality of vent holes 510. The plurality of vent holes 510 may allow air from the fan to exit the vaporizer 500. The fan and the plurality of vent holes 510 may also be used to supply air to the vaporizer 500. For example, the fan may be configured to draw air into the vaporizer 500 from the external environment. The air drawn into the vaporizer 500 can be heated and used as vaporized air. A pump may be used to supply vaporized air to the heated drug to form an aerosolized drug.

[0074] The heating element of the vaporizer 500 may be configured to supply heat to the drug cartridge 300 via the drug assembly port 504. When the drug assembly 200, the connecting element 100, and the retaining chamber 108 are all connected together and connected to the vaporizer 500, the vaporizer 500 can supply heat to at least a portion of the drug cartridge 300 to influence the aerosolization of the drug. The vaporizer 500 can also bring an airflow (e.g., vaporized air) to the drug to move the aerosolized drug into the retaining chamber 108. The vaporizer may have a conductive column that heats the air to its vaporization temperature before supplying it to the drug in the drug cartridge 300, thereby further influencing the transfer of the drug to the aerosolized drug. The vaporized air can be heated by passing it over the conductive column. The vaporized air can swirl around the conductive column, entering from the bottom of the conductive column and exiting from the top. The vaporized air and the heated drug cartridge 300 can influence the transition of the drug from a solid state to vapor, which is then cooled and condensed to form an aerosolized drug suspended in the vaporized air. The aerosolized drug can be suspended in the vaporized air flowing through the drug cartridge 300, thereby supplying the aerosolized drug to the holding chamber 108. The aerosolized drug may be formed from subsequent cooling and thermal condensation in the drug assembly 200 and the holding chamber 108.

[0075] The drug in the drug cartridge 300 inside the drug assembly 200 is subjected to conductive heating, and the drug is also subjected to convection heating by heated vaporized air. Conductive heating to the drug cartridge 300 is supplied by a conductive column inside the vaporizer. Convection heating is supplied by vaporized air that swirls around the conductive column and is then carried through the drug cartridge 300 to heat the drug. In this example, the conductive column is a solid column. Both the vaporized air and the drug cartridge 300 are heated by the conductive column. The drug is heated by both conductive and convection heating. The drug is heated to vapor, and then, by subsequent thermal condensation, an aerosolized drug is formed in the holding chamber.

[0076] The heating element of the vaporizer 500 can supply heat at a temperature sufficient to aerosolize the drug in the drug cartridge 300 (e.g., vaporization temperature). For example, the vaporizer 500 can supply heat at a temperature of about 200 degrees Celsius (°C) to about 260°C. The vaporizer 500 can supply heat at a temperature of about 235°C to the drug cartridge 300 and the amount of air to be vaporized. In some examples, the drug does not reach the vaporization temperature. The flow of air to the drug can move the aerosolized drug to the holding chamber 108 via the drug cartridge 300, the drug cartridge housing 216, and the connecting element 100. In some examples, the vaporizer 500 can provide an airflow rate of about 2 L / min to about 25 L / min. The vaporizer 500 has a capacity of about 2L / min to about 3L / min, about 3L / min to about 4L / min, about 4L / min to about 5L / min, about 5L / min to about 6L / min, about 6L / min to about 7L / min, about 7L / min to about 8L / min, about 8L / min ~ approx. 9L / min, approx. 9L / min ~ approx. 10L / min, approx. 10L / min ~ approx. 11L / min, approx. 11L / min ~ approx. 12L / min, approx. 12L / min ~ approx. 13L / min, approx. 13L / min ~ approx. 14L / min, approx. 14L / min The airflow rate can be approximately 15 L / min, 15 L / min to 16 L / min, 16 L / min to 17 L / min, 17 L / min to 18 L / min, 18 L / min to 19 L / min, 19 L / min to 20 L / min, 20 L / min to 21 L / min, 21 L / min to 22 L / min, 22 L / min to 23 L / min, 23 L / min to 24 L / min, 24 L / min to 25 L / min, or more. The airflow rate may be approximately 7 L / min. The vaporizer 500 can supply heat and airflow until the volume of aerosolized drug and air in the holding chamber 108 is approximately 1 L to 3 L. The vaporizer 500 can supply heat and airflow until the volume of aerosolized drug and air in the holding chamber 108 reaches approximately 2 L.

[0077] The vaporizer 500 can begin filling the holding chamber 108 with the aerosolized drug immediately after heating the drug cartridge 300 and the amount of air to be vaporized and connecting the drug assembly 200 and the connecting element 100 to the drug assembly port 504 of the vaporizer 500. The vaporizer 500 can begin heating the drug cartridge 300 before supplying the airflow. The vaporizer 500 can supply heat during the heating period and then supply airflow during the filling period (e.g., to transport the aerosolized drug to the holding chamber 108 via the amount of air to be vaporized). The heating period can be continued during the filling period. The heating period may be about 30 seconds to about 1 minute, about 1 minute to about 2 minutes, about 2 minutes to about 3 minutes, about 3 minutes to about 4 minutes, about 4 minutes to about 5 minutes, or longer. The filling period may be approximately 10 to 20 seconds, 20 to 30 seconds, 30 to 40 seconds, 40 to 50 seconds, 50 seconds to 1 minute, 1 minute to 2 minutes, or longer. The heating period and the filling period may overlap. For example, the filling period can be started even while the heating period is still in progress.

[0078] After the aerosolized drug is filled into the holding chamber 108, the connecting element 100 can be disconnected from the drug assembly 200 and vaporizer 500. As discussed above, the connecting element 100 can be separated from the drug assembly 200 by compressing the release tabs 102(a) and 102(b), thereby releasing the locking clips 114(a) and 114(b) from the slots 202(a) and 202(b) of the drug assembly 200. The mouthpiece 400 can then be coupled to the connecting element 100 using one or more fitting mechanisms of the connecting element 100 and the mouthpiece 400, as discussed above. When the patient is ready to inhale a dose of the aerosolized drug, the patient can activate the valve of the connecting element 100 by applying force to the mouthpiece 400 as discussed above, and then inhale the aerosolized drug.

[0079] The vaporizer 500 may further include one or more sensors. The vaporizer may include a temperature sensor, a flow rate sensor, a position sensor (e.g., a contact sensor), and / or other sensors to provide information related to the vaporization process. The temperature sensor can measure the temperature supplied to the drug assembly port 504, thereby the temperature supplied to the drug cartridge 300 and the vaporized air. The flow sensor can measure the flow rate of air supplied to the drug assembly port 504 and the flow rate of air supplied to the drug, drug assembly 200, connecting element 100, and holding chamber 108. The position sensor can measure the position of various mating mechanisms, thereby ensuring that the components of the system are properly connected. One or more sensors may communicate with the display screen 502. The connections of the various components of the system may also be ensured by auditory, tactile, and visual feedback. Auditory feedback can be provided by the clicking sound made when components are joined together. Tactile feedback can also be provided when components are joined together. Visual feedback can be provided by examining the various connections and / or indications on the display screen. Furthermore, the vaporizer 500 may be configured to include a detector that determines the time at which the drug assembly 200 is attached to the vaporizer 500. The detector may be a temperature sensor as described herein. The temperature sensor may detect a change in temperature that indicates the drug assembly 200 is attached to the vaporizer 500. When the drug assembly 200 is connected to the vaporizer 500, the temperature sensor may detect a decrease in temperature as the heated air from the vaporizer 500 escapes toward the drug assembly 200. The detector may be a position sensor as described herein (e.g., a contact sensor that can be operated to determine that the drug assembly 200 is properly connected and / or positioned toward the vaporizer 500). Furthermore, the detector may be formed using one or more sensors, including one or more temperature sensors.The detector may be operable to determine a change in temperature using one or more temperature sensors, thereby determining that the drug assembly 200 is connected to the vaporizer 500. The vaporizer 500 may be configured to prevent heating and / or further operation of the drug assembly 200 unless the vaporizer 500 determines that the drug assembly 200 is installed.

[0080] The vaporizer 500 may further include a pulse width modulator. The pulse width modulator may be operable to regulate the flow rate and / or volume of air supplied by the vaporizer 500 to aerosolize a drug. The pulse width modulator can regulate (e.g., control) the flow rate and volume of air supplied by the vaporizer 500 by utilizing a pulse width modulation duty cycle. The pulse width modulator can supply a time-averaged flow rate and total volume of air by periodically switching the air delivery on and off. The pulse width modulator can control the flow rate and volume of air (e.g., the amount of air vaporized) by turning the operation of a pump or fan on and off. In this way, the flow rate and volume of supplied air can be regulated. The pulse width modulator can operate in conjunction with a flow sensor. The pulse width modulator may be an alternative to a flow sensor.

[0081] The vaporizer 500 may have a display screen 502. The display screen 502 may communicate with one or more sensors. The display screen 502 may be operable to display information about the vaporization process. For example, the display screen 502 may display temperature, flow rate, and position data from one or more sensors. Furthermore, the display screen 502 may be operable to receive parameters from the user. The display screen 502 may receive parameters such as a desired dose, a desired vaporization temperature, a desired air flow rate, and other parameters. The display screen 502 may also be used to display instructions to the user regarding the administration of an aerosolized drug. For example, the display screen 502 may show when to connect the drug assembly 200, the connecting element 100, and the retaining chamber 108 to the drug assembly port 504. For example, the display screen 502 may indicate that the drug assembly 200 should be connected to the connecting element 100 and the retaining chamber 108 before being connected to the vaporizer 500. The display screen 502 may also indicate that the holding chamber 108 and connecting element 100 should be removed from the vaporizer 500 while the drug assembly 200 is connected to the vaporizer 500. The display screen 502 may indicate when the dose has been fully filled in the holding chamber 108 (e.g., when aerosolized drug production is complete), thereby instructing the user to remove the connecting element 100 and the holding chamber 108 from the drug assembly 200. The display screen 502 may also include one or more timers to instruct the user when to proceed to a particular step in the vaporization process. The display screen 502 may display errors or warnings regarding improper operation of the vaporizer 500. For example, the display screen 502 may give the user errors or warnings related to improper connection of components, temperature warnings, flow rate warnings, or other warnings.

[0082] The display screen 502 can also display the status of the system, such as completion of proper connection, completion of preheating, aerosolized drug production in progress, completion of aerosolized drug production, or other system status. The display screen 502 can also display one or more indicators, including that the device is ready to proceed to preheating, preheating in progress, preheating complete, ready to begin vaporization, vaporization in progress, and completion of aerosolized drug production. One or more indicators may further include a notification that a predetermined temperature has been reached, a notification instructing the user to confirm that the drug assembly and aerosol containment device are mounted in the vaporizer, a notification instructing the user to begin vaporization, and a notification instructing that vaporization is complete and to proceed immediately with administering the drug to the patient.

[0083] The vaporizer 500 may also include one or more indicator lights. The indicator lights may be LEDs or other lights known in the art. The indicator lights may indicate alarms (e.g., improperly connected components, temperature errors, flow rate errors, or other warnings or errors related to the operation of the system) and completion of steps (e.g., correct connection of components, completion of preheating, generation of aerosolized drug in progress, completion of generation of aerosolized drug, or other steps related to the operation of the system).

[0084] The holding chamber 108 may have one or more sensors, audible or visual indicators that can operate to determine whether the entire volume of the aerosolized drug in the holding chamber 108 has been inhaled. For example, one or more sensors may be mechanical or digital volume sensors that can operate to confirm and indicate that the entire volume of the aerosolized drug has been inhaled by the patient. Notifications, warnings, and other audible and visual indicators may be provided to indicate that the entire volume of the aerosolized drug has been inhaled.

[0085] Further provided herein are methods for administering a drug to a patient in need of the drug. Figure 14 shows an exemplary method 1600 for administering a drug to a patient in need of the drug. Method 1600 can be started in block 1602. In block 1602, a vaporizer can be heated to a predefined vaporization temperature. The predefined vaporization temperature may be about 200°C to about 260°C. The predefined vaporization temperature may be about 235°C.

[0086] In Block 1604, Method 1600 may include immobilizing a drug assembly in an aerosol containment device. The aerosol containment device may include a retaining chamber and a connecting element. The drug assembly may include a drug configured to be aerosolized. The drug may be 5-methoxy-N,N-dimethyltryptamine, tetrahydrocannabinol, enteractogen 3,4-methylenedioxymethamphetamine, ketamine, lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, phenylalkylamine mescaline, other tryptamines, other ergolines, other serotonergic compounds, second-generation psychedelics, nicotine, pentamidine, and / or opioids such as fentanyl, morphine, naloxone, or other drugs designed to be administered in an aerosolized form. The drug may be 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) (i.e., mebufotenin), or a pharmaceutically acceptable salt thereof. The retaining chamber may be configured to contain the aerosolized form of the drug. Securing the drug assembly to the retaining chamber may involve aligning one or more slots of the drug assembly with one or more locking clips of a connecting element attached to the retaining chamber. Other fitting mechanisms may be used to secure the drug assembly to the retaining chamber. For example, a snap-fit ​​mechanism, a magnetic connection mechanism, a latch, a projection and groove mechanism (e.g., a rotary lock), or other known mechanisms known in the art may be used to secure the drug assembly to the retaining chamber. Securing the drug assembly to the retaining chamber provides an airtight channel between the drug assembly and the retaining chamber, thereby preventing fluid leakage to the external environment.

[0087] In block 1606, method 1600 may include securing a drug assembly to a drug assembly port of a vaporizer. Securing a drug assembly to a drug assembly port may include docking the drug assembly to the drug assembly port. Securing a drug assembly to a drug assembly port may include aligning one or more projections on the bottom surface of the drug assembly with grooves in the drug assembly port, and rotating the drug assembly until one or more retaining tabs of a connecting element lock into one or more corresponding tabs of the drug assembly port. One or more projections of the drug assembly may be locked into the grooves using a snap-fit ​​or other locking mechanism. Securing a drug assembly to a drug assembly port provides an airtight channel between the drug assembly port, the drug assembly, the connecting element, and the retaining chamber, thereby preventing fluid leakage to the external environment. One or more tabs of the connecting element may also be removably coupled to one or more slots in the drug assembly port. The slots in the drug assembly port may be configured such that the connecting element and the retaining chamber must be removed from the drug assembly port before the drug assembly can be removed from the drug assembly port. Furthermore, the vaporizer may be configured to determine the time at which the drug assembly is coupled to and / or attached to the vaporizer. For example, a detector may be a sensor for determining when the drug assembly is coupled to the vaporizer. In addition, the detector may be operable to determine a change in temperature by one or more temperature sensors, thereby the detector determines that the drug assembly 200 is connected to the vaporizer 500.

[0088] Method 1600 may include purging a certain amount of air from the vaporizer before securing the drug assembly to the drug assembly port of the vaporizer. Purging a certain amount of air from the vaporizer can prevent any undesirable particles from entering the drug assembly. By purging a certain amount of air before securing the drug assembly to the drug assembly port, the drug assembly port is free of any particles that could otherwise enter the drug assembly when vaporization begins. The volume of purged air may be about 0.1 L to about 0.2 L, about 0.2 L to about 0.3 L, about 0.3 L to about 0.4 L, about 0.4 L to about 0.5 L, about 0.5 L to about 0.6 L, about 0.6 L to about 0.7 L, about 0.7 L to about 0.8 L, about 0.8 L to about 0.9 L, about 0.9 L to about 1 L, or more.

[0089] To facilitate transport, the retaining chamber can be transported in a rolled-up, folded, or otherwise crushed configuration. Therefore, when the retaining chamber is transported in a rolled-up, folded, or crushed configuration, method 1600 may include unrolling, unfolding, or expanding the retaining chamber in any step prior to aerosolizing the drug.

[0090] In block 1608, method 1600 may include aerosolizing a drug into a holding chamber. The drug may be aerosolized by bringing the drug cartridge and vaporized air of the drug assembly to a vaporization temperature. The vaporization temperature may be about 200°C to about 260°C. The vaporization temperature may be about 200°C to about 210°C, about 210°C to about 220°C, about 220°C to about 230°C, about 230°C to about 240°C, about 240°C to about 250°C, about 250°C to about 260°C or higher. The vaporization temperature may be about 235°C. Aerosolizing a drug may further include supplying a certain amount of vaporized air to the drug assembly to move the aerosolized drug through the drug assembly into the holding chamber. The vaporized air may also be heated to a vaporization temperature, thereby further affecting the transfer of the drug to the aerosolized drug. The volume of vaporized air can be approximately 0.5L to 1L, 1L to 1.5L, 1.5L to 2L, 2L to 2.5L, 2.5L to 3L, or more. In the example, the drug does not reach its vaporization temperature. A certain volume of vaporized air can be supplied by the vaporizer's pump. In various examples, a certain volume of vaporized air flows at approximately 1 L / min to 2 L / min, 2 L / min to 3 L / min, 3 L / min to 4 L / min, 4 L / min to 5 L / min, 5 L / min to 6 L / min, 6 L / min to 7 L / min, 7 L / min to 8 L / min, 8 L / min to 9 L / min, 9 L / min to 10 L / min, 10 L / min to 11 L / min, 11 L / min to 12 L / min, 12 L / min to 13 L / min, and 13 L / min to 1 The air can be supplied at flow rates of 4 L / min, approximately 14 L / min to 15 L / min, approximately 15 L / min to 16 L / min, approximately 16 L / min to 17 L / min, approximately 17 L / min to 18 L / min, approximately 18 L / min to 19 L / min, approximately 19 L / min to 20 L / min, approximately 20 L / min to 21 L / min, approximately 21 L / min to 22 L / min, approximately 22 L / min to 23 L / min, approximately 23 L / min to 24 L / min, approximately 24 L / min to 25 L / min, or higher. A certain volume of vaporized air may be approximately 2 L supplied at an air flow rate of approximately 7 L / min.

[0091] Block 1608 can be automated. For example, the vaporizer can be pre-programmed to aerosolize a drug. The vaporizer can be pre-programmed for optimal aerosol generation. The vaporizer can be pre-programmed to supply hot air at a flow rate of 7 L / min and a vaporization temperature of approximately 235°C. The vaporizer can be pre-programmed to deliver a volume of 2 L of vaporized air. In some examples, once the drug assembly and aerosol containment device are connected to the vaporizer, the user can turn on the vaporizer, which is pre-programmed to aerosolize the drug.

[0092] The drug cartridge inside the drug assembly is subjected to conductive heating, and the drug may also be subjected to convective heating by heated vaporized air. Conductive heating to the drug cartridge is supplied by a conductive column inside the vaporizer. Convective heating is supplied by vaporized air swirling around the conductive column and then carried through the drug cartridge to heat the drug. Both the vaporized air and the drug cartridge are heated by the conductive column. The drug is heated by both conductive and convective heating. The drug is heated into vapor, and then subsequent thermal condensation forms an aerosolized drug. The final aerosolized drug for patient inhalation is formed in the holding chamber by subsequent thermal condensation of the vapor. Subsequent thermal condensation may occur in the drug assembly and the holding chamber.

[0093] Method 1600 may include holding the holding chamber in an upright position during the vaporization step of block 1608. Holding the holding chamber in an upright position ensures that the desired dose of drug is completely contained within the holding chamber. An operator can physically hold the holding chamber in an upright position. A holding mechanism, such as a clamp or similar mechanism, can be used to ensure that the holding chamber is held in an upright position during vaporization. The holding chamber can be made of an inherently upright material (e.g., a rigid material). The holding chamber can be made of an upright material, thus allowing the entire volume of the holding chamber to be filled without any resistance from the walls of the holding chamber. The holding chamber can be made of a rigid material that cannot be rolled up. The holding chamber can be made of a flexible material so that it is rollable, foldable, or otherwise crushable. If the holding chamber is made of a flexible material, it can be held upright by an operator or a holding mechanism. The retention chamber may be configured to stand upright to facilitate aerosolized drug formation upon entry of the aerosolized drug into the retention chamber and to minimize the impact of the aerosolized drug on the retention chamber walls. The inner surface of the retention chamber 108 may be antistatic. The inner surface of the retention chamber 108 may have an inlet (e.g., coupled / sealed to a connecting element) configured to minimize adhesion of the aerosolized drug.

[0094] In block 1610, method 1600 may include removing an aerosol containment device from a drug assembly. Removing the aerosol containment device from a drug assembly may include compressing one or more tabs of a connecting element to release one or more locking clips from a slot in the drug assembly. Removing the aerosol containment device from a drug assembly may include compressing the ridges of one or more tabs of a connecting element, each tab being in mechanical communication with a locking clip. If other mating mechanisms are used, the aerosol containment device can be removed from the drug assembly by releasing the mating mechanism from a locked position to an unlocked position. The aerosol containment device can be removed from the drug assembly and vaporizer, but the drug assembly remains coupled to the vaporizer. In the example, the drug assembly cannot be removed from the vaporizer until the aerosol containment device is removed from the vaporizer.

[0095] In block 1612, method 1600 may include securing a mouthpiece to an aerosol containment device. Securing the mouthpiece to the aerosol containment device may include aligning one or more protrusions on the mouthpiece with one or more slots on a connecting element. The protrusions on the mouthpiece can be slidable within the slots of the connecting element. The mouthpiece may further include one or more locking tabs configured to be removably coupled to one or more additional slots on the connecting element. As described above, one or more locking tabs on the mouthpiece can be removably coupled to one or more additional slots on the connecting element. The mouthpiece may be secured to the connecting element, and thereby to the retaining chamber, using other types of mating mechanisms. Other mating mechanisms may include snap-fit ​​mechanisms, magnetic connection mechanisms, latches, protrusion and groove (e.g., rotary lock) mechanisms, or other mechanisms known in the art. Securing the mouthpiece to the aerosol containment device may include at least two steps. Including more than one step can help prevent accidental valve activation.

[0096] Method 1600 may include instructing the patient to sit on a low surface. The surface may be a mattress placed on the floor or slightly elevated from the floor. The patient may sit on the floor. The patient may sit on a bed or a recliner. Protective measures such as side barriers may be included in the position where the patient is sitting.

[0097] In Block 1614, Method 1600 may include administering an aerosolized drug to a patient via a mouthpiece. Administering an aerosolized drug via a mouthpiece may include instructing the patient to firmly press their lips against the mouthpiece and inhale the entire volume of the aerosolized drug from the holding chamber. As the patient firmly presses their lips against the mouthpiece, the mouthpiece translates (e.g., moves) toward a connecting element, applying force to the connecting element. The application of force activates a valve or valve assembly within the connecting element, opening it, thereby allowing the aerosolized drug to flow from the holding chamber into the opening of the mouthpiece. The opening of the mouthpiece delivers the aerosolized drug to the patient. As the patient removes their lips from the mouthpiece, the valve returns to a closed position, thereby preventing the aerosolized drug from escaping from the opening of the mouthpiece. Administration of the aerosolized drug may be performed approximately 1 to 2 minutes, 2 to 3 minutes, or less after the completion of drug aerosolization, to ensure that the desired dose is delivered to the patient.

[0098] The mouthpiece may have one or more struts configured to communicate with a valve on a connecting element and apply force to a link mechanism arm. The patient can apply force to the mouthpiece, causing the struts to apply force to the link mechanism arm. When force is applied to the link mechanism arm, the link mechanism arm moves the valve on the connecting element to the open position. The struts may be sized such that the mouthpiece must translate inward toward the connecting element of the struts in order to apply force to the link mechanism arm. The link mechanism arm may have a spring that returns the valve to the closed position when the force from the patient is removed. When the valve is open, the patient can inhale an aerosolized drug from the holding chamber through the opening of the mouthpiece. Other configurations of the mouthpiece may be used to make contact with and apply force to the link mechanism arm. For example, the lip of the mouthpiece may have one or more struts or other projections that make contact with and apply force to the link mechanism arm.

[0099] The mouthpiece may include one or more vents to allow the patient to inhale a volume greater than the volume in the holding chamber. A mouthpiece may include four vents. Vents may allow the patient to perform "chaser" breathing, meaning that breathing continues beyond the volume held in the holding chamber. Vents may also allow the patient to inhale air from outside the holding chamber after the entire volume of the holding chamber has been inhaled. Chaser breathing may allow for deeper lung inhalation. Furthermore, chaser breathing can prevent the patient from experiencing a feeling of complete blockage when the entire volume of the holding chamber has been inhaled. Method 1600 may further include touching and examining the holding chamber to ensure that the aerosolized drug has been completely inhaled. Touching and examining the holding chamber can be achieved by the user administering the drug. The holding chamber may have one or more sensors, auditory feedback, or visual indicators that are operable to determine whether the entire volume of the aerosolized drug in the holding chamber has been inhaled. For example, one or more sensors may be mechanical or digital volume sensors that are operable to confirm and indicate that the entire volume of the aerosolized drug has been inhaled by the patient. Furthermore, one or more sensors may communicate with the vaporizer's display screen to indicate that the entire volume of the aerosolized drug has been inhaled by the patient. Notifications, warnings, and other auditory and visual indicators indicating that the entire volume of the aerosolized drug has been inhaled may be provided.

[0100] Exemplary embodiments of this disclosure include:

[0101] Embodiment 1. A method for administering a drug to a patient in need of the drug, the method comprising: heating a vaporizer to a predefined vaporization temperature; securing a drug assembly to an aerosol containment device, wherein the drug assembly comprises the drug configured to be aerosolized, and the aerosol containment device is configured to contain the aerosolized drug; securing the drug assembly to a drug assembly port of the vaporizer; vaporizing the drug into the aerosol containment device; removing the aerosol containment device from the drug assembly and the vaporizer; and administering the aerosolized drug to the patient via a mouthpiece.

[0102] The disclosed apparatus, systems, and methods provide physicians and other aerosol handlers with greater consistency in delivery dose uniformity, particle size distribution, and ease of use. For example, the apparatus, systems, and methods provided herein enable the safe and effective administration of aerosols that may contain aerosolized drugs. Furthermore, the disclosed apparatus, systems, and methods enable the production of aerosols with properties (e.g., particle size distribution) suitable for deep lung deposition. In addition, the disclosed apparatus, systems, and methods enable the safe production and administration of psychoactive compounds, thereby reducing the risk of leakage and inadvertent exposure while enabling the production and administration of aerosols.

[0103] Embodiment 2. The method according to Embodiment 1, wherein the aerosol containment device includes a connecting element and a holding chamber.

[0104] Embodiment 3. The method according to Embodiment 2, further comprising holding the holding chamber upright while the drug is being vaporized.

[0105] Embodiment 4. The method according to any one of Embodiments 1-3, further comprising fixing the mouthpiece to the aerosol containment device.

[0106] Embodiment 5. The method according to Embodiment 2 or Embodiment 4 when dependent on Embodiment 2, wherein the holding chamber is configured to stand upright in order to promote aerosolized drug formation when the aerosolized drug enters the holding chamber and to minimize the impact of the aerosolized drug on one or more walls of the holding chamber.

[0107] Embodiment 6. The method according to any one of Embodiments 1 to 5, wherein the drug comprises 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically active salt thereof, cannabinoids, tetrahydrocannabinol, enteractogen 3,4-methylenedioxymethamphetamine, ketamine, lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, phenylalkylamine mescaline, other tryptamines, other ergolines, other serotonergic compounds, second-generation psychedelics, nicotine, pentamidine, and / or opioids such as fentanyl, morphine, and / or naloxone.

[0108] Embodiment 7. The method according to any one of Embodiments 1-6, wherein the vaporizer does not operate unless the aerosol containment device is attached to the drug assembly before the drug assembly is connected to the vaporizer.

[0109] Embodiment 8. The method according to any one of Embodiments 1-7, wherein the user is instructed to attach the aerosol containment device to the drug assembly before connecting the drug assembly to the vaporizer.

[0110] Embodiment 9. The method according to any one of Embodiments 1-8, wherein administering the aerosolized drug includes instructing the patient to firmly press their lips against the mouthpiece and inhale the entire amount of the aerosolized drug from the aerosol containment device.

[0111] Embodiment 10. The method according to Embodiment 9, wherein a valve opens when the patient firmly presses their lips against the mouthpiece, thereby releasing the aerosolized drug.

[0112] Embodiment 11. The method according to Embodiment 2 or any one of Embodiments 3-10 when dependent on Embodiment 2, further comprising touching and examining the holding chamber to ensure that the aerosolized drug has been completely inhaled.

[0113] Embodiment 12. The method according to any one of embodiments 1-11, further comprising confirming that the aerosolized drug has been completely inhaled via one or more sensors configured to determine that the aerosolized drug has been completely inhaled in the aerosol containment device.

[0114] Embodiment 13. The method according to Embodiment 2 or any one of Embodiments 3-12 when dependent on Embodiment 2, wherein securing the drug assembly to the aerosol containment device includes aligning one or more slots of the drug assembly with one or more locking clips of the connecting element.

[0115] Embodiment 14. The method according to Embodiment 2 or any one of Embodiments 3-13 when dependent on Embodiment 2, further comprising winding up and unwinding and / or deploying the holding chamber before vaporizing the drug.

[0116] The holding chamber can be manufactured in a rolled-up configuration to facilitate transport and can be unrolled before use.

[0117] Embodiment 15. The method according to either Embodiment 2 or Embodiments 3-14 when dependent on Embodiment 2, wherein the holding chamber includes a rigid material configured to stand upright.

[0118] The retaining chamber can be made of an upright material, thus allowing the entire volume of the retaining chamber to be filled without any resistance from the retaining chamber walls. For example, the retaining chamber 108 can be made of an upright material, thus allowing the entire volume of the retaining chamber 108 to be filled without any obstruction from the retaining chamber walls.

[0119] Embodiment 16. The method according to any one of Embodiments 14 or 15, when dependent on Embodiment 13 or Embodiment 14, wherein removing the aerosol containment device from the drug assembly comprises compressing one or more release tabs of the connecting element to release one or more locking clips from one or more slots of the drug assembly.

[0120] Embodiment 17. The method according to Embodiment 16, wherein the drug assembly remains connected to the vaporizer when the aerosol containment device is removed from the drug assembly.

[0121] Embodiment 18. The method according to Embodiment 17, wherein one or more retaining tabs of the connecting element are removably coupled to one or more corresponding tabs of the drug assembly port.

[0122] Embodiment 19. The method according to Embodiment 18, wherein the one or more retaining tabs of the connecting element are removably coupled to one or more corresponding tabs of the drug assembly port, thereby preventing the drug assembly from being removed from the drug assembly port before the aerosol containment device is removed from the drug assembly port.

[0123] Embodiment 20. The method according to any one of embodiments 1-19, wherein the aerosol containment device must be removed from the vaporizer before the drug assembly is removed from the vaporizer.

[0124] Embodiment 21. The method according to any one of Embodiments 1-20, wherein the drug assembly cannot be removed from the vaporizer when it is connected to the aerosol containment device.

[0125] Embodiment 22. The method according to any one of Embodiments 1-21, wherein fixing the drug assembly to the drug assembly port of the vaporizer includes docking the drug assembly to the drug assembly port and rotating the drug assembly.

[0126] Embodiment 23. The method according to any one of Embodiments 1-22, further comprising purging a purge amount of air from the vaporizer before securing the drug assembly to the drug assembly port of the vaporizer.

[0127] Embodiment 24. The method according to Embodiment 23, wherein the amount of air used for purging is approximately 0.1 L to approximately 0.5 L.

[0128] Embodiment 25. The method according to any one of Embodiments 1-24, wherein the drug is hydrophilic.

[0129] Embodiment 26. The method according to any one of Embodiments 1-24, wherein the drug is hydrophobic.

[0130] Embodiment 27. The method according to any one of Embodiments 1 to 26, wherein the aerosolized drug is administered to the patient within 3 minutes after the drug has been vaporized.

[0131] Embodiment 28. The method according to any one of Embodiments 1-27, wherein the predefined vaporization temperature is approximately 200°C to approximately 260°C.

[0132] Embodiment 29. The method according to any one of Embodiments 1-28, wherein vaporizing the drug comprises heating a conductive column to the predefined vaporization temperature, passing a vaporized amount of air passing through the drug assembly above the conductive column, thereby exposing the drug to the vaporized amount of air heated to the predefined vaporization temperature, and heating a drug cartridge holding the drug to the predefined vaporization temperature, wherein the heat supplied to the drug cartridge and the heated vaporized amount of air cause the drug to transition to vapor, the vapor then cools and condenses to form an aerosolized drug suspended in the vaporized amount of air, and the vaporized air carries the aerosolized drug to the aerosol containment device.

[0133] Embodiment 30. The method according to Embodiment 29, wherein the final aerosolized drug for administration to the patient is formed during further thermal condensation occurring in the aerosol containment device.

[0134] Embodiment 31. The method according to any one of Embodiments 1-30, wherein the predefined vaporization temperature is approximately 200°C to approximately 260°C.

[0135] Embodiment 32. The method according to Embodiment 31, wherein the predefined vaporization temperature is approximately 235°C.

[0136] Embodiment 33. The method according to any one of Embodiment 29 or Embodiments 30-32 when dependent on Embodiment 29, wherein the amount of air to be vaporized is approximately 0.5 L to approximately 3 L.

[0137] Embodiment 34. The method according to Embodiment 33, wherein the amount of air to be vaporized is approximately 2 L.

[0138] Embodiment 35. The method according to Embodiment 29 or any one of Embodiments 30-34 when dependent on Embodiment 29, wherein the amount of air to be vaporized is supplied at a flow rate of approximately 5 L / min to approximately 25 L / min.

[0139] Embodiment 36. The method according to Embodiment 35, wherein the flow rate is approximately 7 L / min.

[0140] Embodiment 37. The method according to any one of Embodiments 1 to 36, wherein the drug has a melting point of about 50°C to about 80°C.

[0141] Embodiment 38. The method according to any one of Embodiments 1 to 37, wherein the drug has a melting point of about 67.5°C.

[0142] Embodiment 39. The method according to Embodiment 2 or any one of Embodiments 3-39 when dependent on Embodiment 2, wherein the inner surface of the retaining chamber is configured to prevent the aerosolized drug from adhering to it.

[0143] Embodiment 40. The method according to Embodiment 39, wherein the inner surface of the holding chamber is antistatic.

[0144] Embodiment 41. The method according to Embodiment 2 or any one of Embodiments 3-40 when dependent on Embodiment 2, wherein the inlet of the holding chamber is configured to minimize the adhesion of the aerosolized drug.

[0145] Embodiment 42. The method according to any one of Embodiments 1-41, further comprising displaying instructions for the user on the display screen of the vaporizer.

[0146] Embodiment 43. The method according to Embodiment 43, wherein the instructions include fixing the aerosol containment device to the drug assembly before fixing the drug assembly and the aerosol containment device to the vaporizer, and removing only the aerosol containment device from the vaporizer, leaving the drug assembly connected to the vaporizer after the aerosolized drug production is complete.

[0147] Embodiment 44. The method according to any one of Embodiments 1-43, further comprising displaying one or more indicators on the display screen of the vaporizer.

[0148] Embodiment 45. The method according to Embodiment 44, wherein the one or more indicators are one or more of the following: the device is ready to proceed with preheating, preheating in progress, preheating complete, ready to begin vaporization, vaporization in progress, aerosolized drug production complete, temperature measurement, flow rate measurement, position measurement, faulty connection warning, and error.

[0149] Embodiment 46. The method of Embodiment 44 or Embodiment 45, wherein one or more indicators include a notification that the predefined vaporization temperature has been reached, a notification instructing the user to confirm that the drug assembly and aerosol containment device are attached to the vaporizer, a notification instructing the user to start vaporization, and a notification instructing that vaporization is complete and to proceed immediately with administering the drug to the patient.

[0150] Embodiment 47. A system for administering an aerosolized drug, the system comprising: a connecting element having a first end, a second end opposite to the first end, and one or more fitting mechanisms proximal to the first end; and a retaining chamber connected to the second end of the connecting element, the retaining chamber being operable to contain the aerosolized drug.

[0151] Embodiment 48: The system according to Embodiment 47, wherein the retaining chamber includes one or more transparent sections that are operable to indicate the filling level of the retaining chamber.

[0152] One or more transparent sections can allow the user to see the contents inside the holding chamber. For example, the user can assess the filling level of the holding chamber by looking at the contents inside the holding chamber through one or more transparent sections. One or more transparent sections can allow the user to assess whether the holding chamber is full or empty.

[0153] Embodiment 49. The system according to Embodiment 47 or Embodiment 48, wherein the holding chamber has a volume of approximately 0.5 L to approximately 4 L.

[0154] Embodiment 50. The system according to any one of Embodiments 47 to 49, wherein the connecting element and the retaining chamber are coupled via a seal.

[0155] Embodiment 51. The system according to Embodiment 50, wherein the seal is a permanent seal.

[0156] Embodiment 52. The system according to Embodiment 50, wherein the seal is a ring.

[0157] Embodiment 53. The system according to Embodiment 52, wherein the ring is a silicone gasket.

[0158] Embodiment 54. The system according to any one of Embodiments 47-53, wherein the one or more mating mechanisms include a plurality of slots formed on the outside of the connecting element.

[0159] Embodiment 55. The system according to Embodiment 54, wherein the one or more mating mechanisms further include a plurality of locking clips.

[0160] Embodiment 56. The system according to Embodiment 55, wherein the system further comprises a drug assembly, the drug assembly comprising a housing, the housing comprising a housing comprising a first housing fitting mechanism and a housing chamber operable to allow airflow through the housing, and a drug cartridge coupled to the housing, the drug cartridge operable to hold a drug configured to be aerosolized.

[0161] Embodiment 57. The system according to Embodiment 56, wherein the drug cartridge contains the drug configured to be aerosolized.

[0162] Embodiment 58. The system according to Embodiment 57, wherein the drug configured to be aerosolized comprises 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or its pharmaceutically active salt, cannabinoids, tetrahydrocannabinol, enteractogen 3,4-methylenedioxymethamphetamine, ketamine, lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, phenylalkylamine mescaline, other tryptamines, other ergolines, other serotonergic compounds, second-generation psychedelics, nicotine, pentamidine, and / or opioids such as fentanyl, morphine, and / or naloxone.

[0163] Embodiment 59. The system according to Embodiments 56-58, wherein the first housing fitting mechanism is configured to be removably coupled to the connecting element.

[0164] Embodiment 60. The system according to Embodiment 59, wherein the first housing fitting mechanism includes a first slot and a second slot on opposing sides of the housing.

[0165] Embodiment 61. The system according to Embodiment 60, wherein the plurality of locking clips are configured to be removably coupled to the first slot and the second slot of the housing.

[0166] Embodiment 62. The system according to Embodiment 61, wherein the connecting element further comprises a valve, and the valve is set in the open position when the drug assembly is connected to the connecting element.

[0167] Embodiment 63. The system according to Embodiment 62, wherein the housing applies force to the valve, causing the valve to act in the open position.

[0168] Embodiment 64. The system according to Embodiment 63, wherein the open state allows fluid to flow into the holding chamber.

[0169] Embodiment 65. The system according to Embodiment 62, wherein the valve has a closed state configured to prevent fluid from flowing into or out of the retaining chamber.

[0170] Embodiment 66. The system according to Embodiment 65, wherein the valve is in the closed state when no force is applied.

[0171] Embodiment 67. The system according to Embodiment 66, wherein the valve transitions to the closed state when the drug assembly is disconnected from the connecting element and the retaining chamber.

[0172] Embodiment 68. The system according to any one of Embodiment 60 or Embodiments 61-67, wherein the system further comprises a vaporizer, the vaporizer comprising a drug assembly port operable to be removably coupled to a port fitting mechanism and a connecting element fitting mechanism of the housing, and a heating element operable to heat a vaporized amount of air and at least a portion of the drug cartridge, wherein the heat supplied to the portion of the drug cartridge vaporizes the drug, the heated vaporized amount of air passes through the drug cartridge, thereby vaporizing the drug, and the vaporized drug subsequently cools and condenses to form the aerosolized drug.

[0173] Embodiment 69. The system according to Embodiment 68, wherein the vaporizer further includes one or more sensors.

[0174] Embodiment 70. The system according to Embodiment 69, wherein the one or more sensors include a temperature sensor, a flow sensor, and a position sensor.

[0175] Embodiment 71. The system according to any one of Embodiments 68 or 69-70, wherein the vaporizer further includes a pulse width modulator that is operable to adjust the flow rate and volume of the amount of air to be heated and vaporized.

[0176] Embodiment 72. The system according to Embodiment 71, wherein the vaporizer further includes a pump or fan capable of supplying the heated vaporized amount of air, and the pulse width modulator controls the pump or the fan.

[0177] Embodiment 73. The system according to any one of Embodiments 68 or 69-72, wherein the drug assembly port includes a groove.

[0178] Embodiment 74. The system according to Embodiment 73, wherein the port mating mechanism includes two or more projections that are operable to be received inside the groove.

[0179] Embodiment 75. The system according to Embodiment 74, wherein rotating the drug assembly and the connecting element while the two or more projections of the port mating mechanism are in the grooves locks one or more retaining tabs of the connecting element with one or more corresponding tabs of the drug assembly port, thereby coupling the drug assembly and the connecting element to the drug assembly port.

[0180] Embodiment 76. The system according to Embodiment 55 or any one of Embodiments 56-74 when dependent on Embodiment 55, further comprising a mouthpiece operable to couple with the connecting element, the mouthpiece comprising four mouthpiece protrusions, each mouthpiece protrusion operable to be received into a respective slot of the connecting element; at least one mouthpiece tab operable to couple detachably to the connecting element; and an opening that fluidly communicates with the connecting element and the retaining chamber when the mouthpiece is coupled to the connecting element.

[0181] Embodiment 77. The system according to Embodiment 76, wherein the plurality of slots of the connecting element are configured to receive and connect the at least one mouthpiece tab.

[0182] Embodiment 78. The system according to Embodiment 77, wherein the connecting element further includes a valve.

[0183] Embodiment 79. The system according to Embodiment 78, wherein the valve is operated to an open state by applying force to the mouthpiece and translating the mouthpiece inward toward the connecting element.

[0184] Embodiment 80. The system according to Embodiment 79, wherein the aerosolized drug is administered to the patient when the patient presses their lips against the mouthpiece, thereby translating the mouthpiece inward toward the connecting element, and the valve is set in the open position for inhalation.

[0185] Embodiment 81. The system according to Embodiment 80, wherein the valve is closed when no force is applied to it.

[0186] Embodiment 82. The system according to Embodiment 81, wherein the mouthpiece and / or the connecting element further includes an O-ring configured to reduce the force required to set the valve in the open position.

[0187] Embodiment 83. The system according to Embodiment 82, wherein the O-ring is configured to ensure that the valve is in the closed position when no force is applied to the valve.

[0188] Embodiment 84. The system according to Embodiment 82 or Embodiment 83, wherein the O-ring is a parylene-coated O-ring.

[0189] Embodiment 85. A drug assembly configured to contain a drug, the drug assembly comprising a housing, the housing including a first fitting mechanism and a chamber operable to allow airflow through the housing, and a drug cartridge connected to the housing, the drug cartridge being connected to the first fitting mechanism.

[0190] Embodiment 86. The drug assembly according to Embodiment 85, further comprising a second mating mechanism that is operable to removably connect the housing to a mating mechanism of a connecting element.

[0191] Embodiment 87. The drug assembly according to Embodiment 86, wherein the second fitting mechanism includes two slots located on opposing sides of the housing.

[0192] Embodiment 88. The drug assembly according to Embodiment 87, wherein the connecting element fitting mechanism includes two locking clips that are operable to removably connect to the two slots of the housing.

[0193] Embodiment 89. The drug assembly according to Embodiment 88, further comprising a third mating mechanism that is operable to allow the housing to be detachably coupled to a drug assembly port of a vaporizer.

[0194] Embodiment 90. The drug assembly according to Embodiment 89, wherein two retaining tabs of the connecting element mating mechanism are configured to protrude through the drug assembly and to be removably coupled to two corresponding tabs of the drug assembly port.

[0195] Embodiment 91. The drug assembly according to Embodiment 90, wherein the third fitting mechanism includes two or more projections that are operable to be received inside a groove of the drug assembly port of the vaporizer.

[0196] Embodiment 92. The drug assembly according to Embodiment 91, wherein the drug assembly is rotated and the two retaining tabs of the connecting element fitting mechanism are locked onto the corresponding two tabs of the drug assembly port, thereby locking the two or more projections into the grooves of the drug assembly port of the vaporizer.

[0197] Embodiment 93. The drug assembly according to Embodiment 92, wherein when the two retaining tabs are locked to the corresponding two tabs of the drug assembly port, the two retaining tabs of the connecting element mating mechanism prevent rotation of the drug assembly and the connecting element.

[0198] Embodiment 94. A drug for use as a pharmaceutical, wherein the drug is administered to a patient in need by the method described in any of Embodiments 1-5 or 7-46.

[0199] Embodiment 95. A drug for use in the treatment of a disease or disorder, wherein the treatment comprises administering the drug to a patient in need thereof, and the drug is administered by a method defined in either Embodiment 1-5 or 7-46.

[0200] Embodiment 96. A drug for use as a pharmaceutical, wherein the drug is administered to a patient in need by a system defined in any of Embodiments 47-84.

[0201] Embodiment 97. A drug for use in the treatment of a disease or disorder, wherein the treatment comprises administering the drug to a patient in need thereof, and the drug is administered by a system defined in any of Embodiments 47-84.

[0202] Embodiment 98. A drug for use as a pharmaceutical, wherein the drug is contained within a drug assembly as defined in any of Embodiments 85-93.

[0203] Embodiment 99. A drug for use in the treatment of a disease or disorder, wherein the drug is contained within a drug assembly as defined in any of Embodiments 85-93.

[0204] Apparatus 100. A drug for use according to any one of Apparatus 95, 97, or 99, wherein the disease or disorder is a mental disorder or a nervous system disorder.

[0205] Embodiment 101. A drug for use according to any one of Embodiments 94-100, wherein the drug comprises 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or its pharmaceutically active salt, cannabinoids, tetrahydrocannabinol, enteractogen 3,4-methylenedioxymethamphetamine, ketamine, lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, phenylalkylamine mescaline, other tryptamines (e.g., tryptamines other than 5-MeO-DMT and N,N-dimethyltryptamine), other ergolines, other serotonergic compounds, second-generation psychedelics, nicotine, pentamidine, and / or opioids such as fentanyl, morphine, and / or naloxone.

[0206] Embodiment 102. A drug for use according to any one of Embodiments 94-100, wherein the drug is 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically active salt thereof, cannabinoids, tetrahydrocannabinol, enteractogen 3,4-methylenedioxymethamphetamine, ketamine, lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, phenylalkylamine mescaline, other tryptamines (e.g., tryptamines other than 5-MeO-DMT and N,N-dimethyltryptamine), other ergolines, other serotonergic compounds, second-generation psychedelics, nicotine, pentamidine, and / or opioids such as fentanyl, morphine, and / or naloxone.

[0207] Embodiment 103. The drug for use according to Embodiment 102, wherein the second-generation psychedelic is selected from the group consisting of deuterated tryptamine and non-hallucinogenic psychoplastogen, and optionally the non-hallucinogenic psychoplastogen is a tabernanthalog, N-dimethylaminoisotryptamine, or a derivative thereof.

[0208] Embodiment 104. The drug for use according to Embodiment 101, wherein the drug comprises 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically active salt thereof, and preferably the drug comprises a free base of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).

[0209] Embodiment 105. The drug for use according to Embodiment 102, wherein the drug is 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically active salt thereof, and preferably the drug is a free base of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).

[0210] Apparatus 106. A drug for use according to any one of Apparatus 95, 97, 99, or 101-104, wherein the disease or disorder is selected from the group consisting of postpartum depression, sleep disorders, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorders, post-traumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorders, psychoactive substance abuse, epilepsy, chemotherapy-related nausea, acute pain, chronic pain, phantom limb pain, migraine, multiple sclerosis, multiple sclerosis seizures, schizophrenia, insomnia, rheumatoid arthritis, psychosis, HIV-induced anorexia, sleep apnea, alcohol use disorder, suicidal ideation, psychoactive substance use disorder, smoking cessation, Parkinson's disease, dementia, pleuropneumonia, parasitic conditions, Pneumocystis pneumonia, HIV-related dementia, cough, diarrhea, nausea, opioid abuse, seizures, and shortness of breath.

[0211] Embodiment 107. A drug for use according to Embodiment 100 or 106, wherein the disease or disorder is selected from the group consisting of postpartum depression, sleep disorders, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorders, post-traumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorders, and abuse of psychoactive substances.

[0212] Embodiment 108. The drug for use according to any one of Embodiments 95, 97, 99, 101, 104, or 106, wherein the drug comprises 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically active salt thereof, and the disease or disorder is selected from the group consisting of postpartum depression, sleep disorders, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorders, post-traumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorders, and abuse of psychoactive substances.

[0213] Embodiment 109. The drug for use according to any one of Embodiments 95, 97, 99, 102, 105, or 106, wherein the drug is 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically active salt thereof, and the disease or disorder is selected from the group consisting of postpartum depression, sleep disorders, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorders, post-traumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorders, and abuse of psychoactive substances.

[0214] Embodiment 110. The drug for use according to Embodiment 108, wherein the drug comprises 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically active salt thereof, and the disease or disorder is major depressive disorder.

[0215] Embodiment 111. The drug for use according to Embodiment 109, wherein the drug is 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically active salt thereof, and the disease or disorder is major depressive disorder.

[0216] Apparatus 112. A drug for use according to any one of Apparatus 95, 97, 99, 101, or 106, wherein the drug comprises a cannabinoid, and the disease or disorder is selected from the group consisting of epilepsy, chemotherapy-associated nausea, chronic pain, multiple sclerosis seizures, anxiety disorders, post-traumatic stress disorder, major depressive disorder, bipolar disorder, schizophrenia, and insomnia.

[0217] Embodiment 113. A drug for use according to any one of Embodiments 95, 97, 99, 102, or 106, wherein the drug is a cannabinoid, and the disease or disorder is selected from the group consisting of epilepsy, chemotherapy-associated nausea, chronic pain, multiple sclerosis seizures, anxiety disorders, post-traumatic stress disorder, major depressive disorder, bipolar disorder, schizophrenia, and insomnia.

[0218] Embodiment 114. The drug for use according to any one of Embodiments 95, 97, 99, 101, or 106, wherein the drug comprises tetrahydrocannabinol, and the disease or disorder is selected from the group consisting of HIV-induced anorexia, chemotherapy-associated nausea, chronic pain, sleep apnea syndrome, and multiple sclerosis.

[0219] Embodiment 115. The drug for use according to any one of Embodiments 95, 97, 99, 102, or 106, wherein the drug is tetrahydrocannabinol, and the disease or disorder is selected from the group consisting of HIV-induced anorexia, chemotherapy-associated nausea, chronic pain, sleep apnea syndrome, and multiple sclerosis.

[0220] Embodiment 116. The drug for use according to any one of Embodiments 95, 97, 99, 101, or 106, wherein the drug comprises the enterogen 3,4-methylenedioxymethamphetamine, and the disease or disorder is selected from the group consisting of post-traumatic stress disorder, major depressive disorder, and alcohol use disorder.

[0221] Embodiment 117. A drug for use according to any one of Embodiments 95, 97, 99, 102, or 106, wherein the drug is an enterogen 3,4-methylenedioxymethamphetamine, and the disease or disorder is selected from the group consisting of post-traumatic stress disorder, major depressive disorder, and alcohol use disorder.

[0222] Embodiment 118. A drug for use according to any one of Embodiments 95, 97, 99, 101, or 106, wherein the drug comprises ketamine, and the disease or disorder is selected from the group consisting of acute pain, nausea, suicidal ideation, psychoactive substance use disorder, and post-traumatic stress disorder.

[0223] Embodiment 119. A drug for use according to any one of Embodiments 95, 97, 99, 102, or 106, wherein the drug is ketamine and the disease or disorder is selected from the group consisting of acute pain, nausea, suicidal ideation, drug dependence, and post-traumatic stress disorder.

[0224] Embodiment 120. The drug for use according to any one of Embodiments 95, 97, 99, 101, or 106, wherein the drug comprises lysergic acid diethylamide, and the disease or disorder is selected from the group consisting of alcohol use disorder, anxiety disorder, psychoactive substance use disorder, and phantom limb pain.

[0225] Embodiment 121. The drug for use according to any one of Embodiments 95, 97, 99, 102, or 106, wherein the drug is lysergic acid diethylamide, and the disease or disorder is selected from the group consisting of alcohol use disorder, anxiety disorder, psychoactive substance use disorder, and phantom limb pain.

[0226] Embodiment 122. A drug for use according to any one of Embodiments 95, 97, 99, 101, or 106, wherein the drug comprises psilocybin, and the disease or disorder is selected from the group consisting of anxiety disorders, psychoactive substance use disorders, smoking cessation, obsessive-compulsive disorder, psychosis, post-traumatic stress disorder, and migraine.

[0227] Embodiment 123. A drug for use according to any one of Embodiments 95, 97, 99, 102, or 106, wherein the drug is psilocybin, and the disease or disorder is selected from the group consisting of anxiety disorders, psychoactive substance use disorders, smoking cessation, obsessive-compulsive disorder, psychosis, post-traumatic stress disorder, and migraine.

[0228] Embodiment 124. The drug for use according to any one of embodiments 95, 97, 99, 101, and 106, wherein the drug comprises N,N-dimethyltryptamine, and the disease or disorder is selected from the group consisting of postpartum depression, sleep disorders, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorders, post-traumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorders, psychoactive substance abuse, and Parkinson's disease.

[0229] Embodiment 125. The drug for use according to any one of embodiments 95, 97, 99, 102, and 106, wherein the drug is N,N-dimethyltryptamine, and the disease or disorder is selected from the group consisting of postpartum depression, sleep disorders, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorders, post-traumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorders, psychoactive substance abuse, and Parkinson's disease.

[0230] Embodiment 126. The drug for use according to any one of Embodiments 95, 97, 99, 101, or 106, wherein the drug comprises phenylalkylamine mescaline, and the disease or disorder is selected from the group consisting of alcohol use disorder, psychoactive substance use disorder, post-traumatic stress disorder, and anxiety disorder.

[0231] Embodiment 127. The drug for use according to any one of Embodiments 95, 97, 99, 102, or 106, wherein the drug is phenylalkylamine mescaline, and the disease or disorder is selected from the group consisting of alcohol use disorder, psychoactive substance use disorder, post-traumatic stress disorder, and anxiety disorder.

[0232] Embodiment 128. A drug for use according to any one of Embodiments 95, 97, 99, 101, or 106, wherein the drug comprises tryptamine other than 5-MeO-DMT, psilocybin, or N,N-dimethyltryptamine, and the disease or disorder is selected from the group consisting of anxiety disorders, schizophrenia, bipolar disorder, psychoactive substance use disorder, and chronic pain.

[0233] Embodiment 129. A drug for use according to any one of Embodiments 95, 97, 99, 102, or 106, wherein the drug is a tryptamine other than 5-MeO-DMT, psilocybin, or N,N-dimethyltryptamine, and the disease or disorder is selected from the group consisting of anxiety disorders, schizophrenia, bipolar disorder, psychoactive substance use disorder, and chronic pain.

[0234] Embodiment 130. A drug for use according to any one of Embodiments 95, 97, 99, 101, or 106, wherein the drug comprises an ergoline other than lysergic acid diethylamide (LSD), and the disease or disorder is selected from the group consisting of migraine, Parkinson's disease, and dementia.

[0235] Embodiment 131. A drug for use according to any one of Embodiments 95, 97, 99, 102, or 106, wherein the drug is an ergoline other than lysergic acid diethylamide (LSD), and the disease or disorder is selected from the group consisting of migraine, Parkinson's disease, and dementia.

[0236] Embodiment 132. A drug for use according to any one of Embodiments 95, 97, 99, 101, or 106, wherein the drug comprises a serotonergic compound, and the disease or disorder is selected from the group consisting of anxiety disorders, obsessive-compulsive disorders, eating disorders, chronic pain, and post-traumatic stress disorder.

[0237] Embodiment 133. A drug for use according to any one of Embodiments 95, 97, 99, 102, or 106, wherein the drug is a serotonergic compound, and the disease or disorder is selected from the group consisting of anxiety disorders, obsessive-compulsive disorder, eating disorders, chronic pain, and post-traumatic stress disorder.

[0238] Embodiment 134. The drug for use according to any one of Embodiments 95, 97, 99, 101, or 106, wherein the drug comprises nicotine, and the disease or disorder is selected from the group consisting of smoking cessation, Parkinson's disease, dementia, preferably Parkinson's disease and dementia.

[0239] Embodiment 135. The drug for use according to any one of Embodiments 95, 97, 99, 102, or 106, wherein the drug is nicotine, and the disease or disorder is selected from the group consisting of smoking cessation, Parkinson's disease, and dementia, preferably Parkinson's disease and dementia.

[0240] Embodiment 136. A drug for use according to any one of Embodiments 95, 97, 99, 101, or 106, wherein the drug comprises pentamidine, and the disease or disorder is selected from the group consisting of parasitic diseases, Pneumocystis pneumonia, and HIV-associated dementia.

[0241] Embodiment 137. A drug for use according to any one of Embodiments 95, 97, 99, 102, or 106, wherein the drug is pentamidine, and the disease or disorder is selected from the group consisting of parasitic diseases, Pneumocystis pneumonia, and HIV-associated dementia.

[0242] Embodiment 138. The drug for use according to Embodiment 136 or 137, wherein the parasitic disease is selected from the group consisting of African trypanosomal disease, Leish mania, and Balamutia.

[0243] Embodiment 139. A drug for use according to any one of Embodiments 95, 97, 99, 101, or 106, wherein the drug comprises fentanyl, morphine, and / or naloxone, and the disease or disorder is selected from the group consisting of acute pain, chronic pain, shortness of breath, opioid abuse, cough, and diarrhea.

[0244] Embodiment 140. A drug for use according to any one of Embodiments 95, 97, 99, 102, or 106, wherein the drug is fentanyl, morphine, and / or naloxone, and the disease or disorder is selected from the group consisting of acute pain, chronic pain, shortness of breath, opioid abuse, cough, and diarrhea.

[0245] Apparatus 141. A drug for use according to any one of Apparatus 95, 97, 99, 101, or 106, wherein the drug comprises a second-generation psychedelic, and the disease or disorder is selected from the group consisting of postpartum depression, sleep disorders, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorders, post-traumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorders, and psychoactive substance abuse disorders.

[0246] Embodiment 142. A drug for use according to any one of Embodiments 95, 97, 99, 102, or 106, wherein the drug is a second-generation psychedelic, and the disease or disorder is selected from the group consisting of postpartum depression, sleep disorders, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorders, post-traumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorders, and psychoactive substance abuse disorders.

[0247] All numbered embodiments are embodiments of the present invention. While various information has been used to describe the embodiments within the appended claims, it is not intended to limit the claims on any particular feature or configuration, as a person skilled in the art can derive various embodiments. Furthermore, while some subject matter may be described in language specific to structural features and / or method steps, it should be understood that the subject matter as defined in the appended claims is not necessarily limited to these described features or actions. Such functionality may be distributed or performed in different ways by components other than those specified herein. Rather, the described features and steps are disclosed as possible components of the systems and methods within the appended claims.

Claims

1. A system for administering an aerosolized drug, wherein the system is A connecting element having a first end, a second end facing the first end, and one or more fitting mechanisms proximal to the first end, The system includes a retaining chamber connected to the second end of the connecting element, wherein the retaining chamber is operable to contain the aerosolized drug.

2. The system according to claim 1, wherein the retaining chamber includes one or more transparent sections that are operable to indicate the filling level of the retaining chamber.

3. The system according to claim 1, wherein the holding chamber has a volume of about 0.5 L to about 4 L.

4. The system according to claim 3, wherein the connecting element and the retaining chamber are coupled via a seal.

5. The system according to claim 4, wherein the seal is a permanent seal.

6. The system according to claim 4, wherein the seal is a ring.

7. The system according to claim 6, wherein the ring is a silicone gasket.

8. The system according to claim 1, wherein the one or more mating mechanisms include a plurality of slots formed on the outside of the connecting element.

9. The system according to claim 8, wherein the one or more fitting mechanisms further include a plurality of locking clips.

10. The system further includes a drug assembly, and the drug assembly is It is a housing, First housing fitting mechanism, and The housing includes a housing chamber that is operable to allow airflow through the housing, and The system according to claim 9, comprising a drug cartridge coupled to the housing, the drug cartridge being operable to hold a drug configured to be aerosolized.

11. The system according to claim 10, wherein the first housing fitting mechanism is configured to be detachably coupled to the connecting element.

12. The system according to claim 11, wherein the first housing fitting mechanism includes a first slot and a second slot on opposing sides of the housing.

13. The system according to claim 12, wherein the plurality of locking clips are configured to be removably coupled to the first slot and the second slot of the housing.

14. The system according to claim 13, wherein the connecting element further comprises a valve, and when the drug assembly is connected to the connecting element, the valve is set in an open position.

15. The system according to claim 14, wherein the housing applies force to the valve, causing the valve to operate in the open position.

16. The system according to claim 15, wherein the open state allows fluid to flow into the holding chamber.

17. The system according to claim 14, wherein the valve has a closed state configured to prevent fluid from flowing into or out of the retaining chamber.

18. The system according to claim 17, wherein the valve is in the closed state when no force is applied.

19. The system according to claim 18, wherein the valve transitions to the closed state when the drug assembly is disconnected from the connecting element and the holding chamber.

20. The system further includes a vaporizer, and the vaporizer A drug assembly port that is operable to be detachably coupled to the port mating mechanism and connecting element mating mechanism of the housing, and Includes a heating element capable of heating the vaporized air and at least a portion of the drug cartridge, The heat supplied to the part of the drug cartridge vaporizes the drug, The heated vaporized air passes through the drug cartridge, thereby vaporizing the drug. The system according to claim 12, wherein the vaporized drug is subsequently cooled and condensed to form the aerosolized drug.

21. The system according to claim 20, wherein the vaporizer further includes one or more sensors.

22. The system according to claim 21, wherein the one or more sensors include a temperature sensor, a flow sensor, and / or a position sensor.

23. The system according to claim 20, wherein the vaporizer further includes a pulse width modulator that is operable to adjust the flow rate and volume of the amount of air to be heated and vaporized.

24. The system according to claim 23, wherein the vaporizer further includes a pump or fan capable of supplying the heated vaporized amount of air, and the pulse width modulator controls the pump or the fan.

25. The system according to claim 20, wherein the drug assembly port includes a groove.

26. The system according to claim 25, wherein the port fitting mechanism includes two or more projections that are operable to be received inside the groove.

27. The system according to claim 26, wherein rotating the drug assembly and the connecting element while the two or more protrusions of the port mating mechanism are in the grooves locks one or more retaining tabs of the connecting element with one or more corresponding tabs of the drug assembly port, thereby coupling the drug assembly and the connecting element to the drug assembly port.

28. The system further includes a mouthpiece that is operable to couple with the connecting element, the mouthpiece is Four mouthpiece protrusions, each of which is operable so as to be received into the respective slot of the connecting element, At least one mouthpiece tab that is operable to be detachably coupled to the aforementioned connecting element, and The system according to claim 9, further comprising an opening that fluidly communicates with the connecting element and the retaining chamber when the mouthpiece is coupled to the connecting element.

29. The system according to claim 28, wherein the plurality of slots of the connecting element are configured to receive and connect to the at least one mouthpiece tab.

30. The system according to claim 29, wherein the connecting element further includes a valve.

31. The system according to claim 30, wherein the valve is operated to an open state by applying force to the mouthpiece and translating the mouthpiece inward toward the connecting element.

32. The system according to claim 31, wherein the patient presses their lips against the mouthpiece, thereby translating the mouthpiece inward toward the connecting element, and the aerosolized drug is administered to the patient when the valve is set to the open position and inhaled.

33. The system according to claim 32, wherein the valve is in a closed state when no force is applied to it.

34. The system according to claim 33, wherein the mouthpiece and / or the connecting element further includes an O-ring configured to reduce the force required to set the valve in the open position.

35. The system according to claim 34, wherein the O-ring is configured to ensure that the valve is in the closed state when no force is applied to the valve.

36. The system according to claim 34, wherein the O-ring is a parylene-coated O-ring.

37. A drug assembly configured to contain a drug, wherein the drug assembly is It is a housing, First fitting mechanism, and The housing includes a chamber that is operable to allow airflow through the housing, and Includes a drug cartridge connected to the housing, The drug cartridge is connected to the first fitting mechanism, the drug assembly.

38. The drug assembly according to claim 37, further comprising a second mating mechanism that is operable to removably connect the housing to a mating mechanism of a connecting element.

39. The drug assembly according to claim 38, wherein the second fitting mechanism includes two slots located on opposing sides of the housing.

40. The drug assembly according to claim 39, wherein the connecting element fitting mechanism includes two locking clips that are operable to removably connect to the two slots of the housing.

41. The drug assembly according to claim 40, further comprising a third mating mechanism that is operable to allow the housing to be detachably coupled to a drug assembly port of a vaporizer.

42. The drug assembly according to claim 41, wherein the two retaining tabs of the connecting element mating mechanism are configured to protrude through the drug assembly and to be removably coupled to two corresponding tabs of the drug assembly port.

43. The drug assembly according to claim 42, wherein the third fitting mechanism includes two or more projections that are operable to be received inside the groove of the drug assembly port of the vaporizer.

44. The drug assembly according to claim 43, wherein the drug assembly is rotated and the two retaining tabs of the connecting element fitting mechanism are locked onto the corresponding two tabs of the drug assembly port, thereby locking the two or more protrusions into the grooves of the drug assembly port of the vaporizer.

45. The drug assembly according to claim 44, wherein the two retaining tabs of the connecting element mating mechanism prevent rotation of the drug assembly and the connecting element when the two retaining tabs are locked onto the corresponding two tabs of the drug assembly port.

46. The drug assembly according to claim 37, wherein the drug is included in the drug assembly.

47. The drug assembly according to claim 46, wherein the drug is contained in the drug cartridge.

48. The drug assembly according to claim 46, wherein the drug comprises 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically active salt thereof, cannabinoids, tetrahydrocannabinol, enteractogen 3,4-methylenedioxymethamphetamine, ketamine, lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, phenylalkylamine mescaline, other tryptamines, other ergolines, other serotonergic compounds, second-generation psychedelics, nicotine, pentamidine, and / or opioids such as fentanyl, morphine, and / or naloxone.

49. The drug assembly according to claim 46, wherein the drug is 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically active salt thereof, cannabinoids, tetrahydrocannabinol, enteractogen 3,4-methylenedioxymethamphetamine, ketamine, lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, phenylalkylamine mescaline, other tryptamines, other ergolines, other serotonergic compounds, second-generation psychedelics, nicotine, pentamidine, and / or opioids such as fentanyl, morphine, and / or naloxone.

50. A method for administering the drug to a patient who requires the drug, wherein the method is Heat the vaporizer to a predefined vaporization temperature. The fixation of a drug assembly to an aerosol containment device, wherein the drug assembly comprises the drug configured to be aerosolized, and the aerosol containment device is configured to contain the aerosolized drug. To fix the drug assembly to the drug assembly port of the vaporizer, The drug is vaporized into the aerosol containment device. Removing the aerosol containment device from the drug assembly and the vaporizer, and The method comprising administering the aerosolized drug to the patient via a mouthpiece.

51. The method according to claim 50, wherein the aerosol containment device includes a connecting element and a holding chamber.

52. The method according to claim 51, further comprising keeping the holding chamber upright while the drug is being vaporized.

53. The method according to claim 50, further comprising fixing the mouthpiece to the aerosol containment device.

54. The method according to claim 51, wherein the holding chamber is configured to stand upright in order to promote the formation of an aerosolized drug when the aerosolized drug enters the holding chamber and to minimize the impact of the aerosolized drug on one or more walls of the holding chamber.

55. The method according to claim 50, wherein the drug comprises 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically active salt thereof, cannabinoids, tetrahydrocannabinol, enteractogen 3,4-methylenedioxymethamphetamine, ketamine, lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, phenylalkylamine mescaline, other tryptamines, other ergolines, other serotonergic compounds, second-generation psychedelics, nicotine, pentamidine, and / or opioids such as fentanyl, morphine, and / or naloxone.

56. The method according to claim 50, wherein the vaporizer will not operate unless the aerosol containment device is attached to the drug assembly before the drug assembly is connected to the vaporizer.

57. The method according to claim 50, wherein the user is instructed to attach the aerosol containment device to the drug assembly before connecting the drug assembly to the vaporizer.

58. The method according to claim 50, wherein administering the aerosolized drug includes instructing the patient to firmly press their lips against the mouthpiece and inhale the entire amount of the aerosolized drug from the aerosol containment device.

59. The method according to claim 58, wherein when the patient firmly presses their lips against the mouthpiece, a valve opens, thereby releasing the aerosolized drug.

60. The method according to claim 51, further comprising touching and examining the holding chamber to ensure that the aerosolized drug has been completely inhaled.

61. The method according to claim 50, further comprising confirming that the aerosolized drug has been completely inhaled via one or more sensors configured to determine that the aerosolized drug has been completely inhaled in the aerosol containment device.

62. The method according to claim 51, wherein securing the drug assembly to the aerosol containment device includes aligning one or more slots of the drug assembly with one or more locking clips of the connecting element.

63. The method according to claim 51, further comprising winding up and unwinding and / or deploying the holding chamber before vaporizing the drug.

64. The method according to claim 51, wherein the holding chamber includes a rigid material configured to stand upright.

65. The method according to claim 62, wherein removing the aerosol containment device from the drug assembly comprises compressing one or more release tabs of the connecting element to release one or more locking clips from one or more slots of the drug assembly.

66. The method according to claim 65, wherein when the aerosol containment device is removed from the drug assembly, the drug assembly remains connected to the vaporizer.

67. The method according to claim 66, wherein one or more retaining tabs of the connecting element are removably coupled to one or more corresponding tabs of the drug assembly port.

68. The method according to claim 67, wherein one or more retaining tabs of the connecting element are detachably coupled to one or more corresponding tabs of the drug assembly port, thereby preventing the drug assembly from being removed from the drug assembly port before the aerosol containment device is removed from the drug assembly port.

69. The method according to claim 50, wherein the aerosol containment device must be removed from the vaporizer before the drug assembly is removed from the vaporizer.

70. The method according to claim 50, wherein the drug assembly cannot be removed from the vaporizer when it is connected to the aerosol containment device.

71. The method according to claim 50, wherein fixing the drug assembly to the drug assembly port of the vaporizer includes docking the drug assembly to the drug assembly port and rotating the drug assembly.

72. The method according to claim 50, further comprising purging a purge amount of air from the vaporizer before fixing the drug assembly to the drug assembly port of the vaporizer.

73. The method according to claim 72, wherein the amount of air used for purging is approximately 0.1 L to approximately 0.5 L.

74. The method according to claim 50, wherein the drug is hydrophilic.

75. The method according to claim 50, wherein the drug is hydrophobic.

76. The method according to claim 50, wherein the aerosolized drug is administered to the patient within three minutes after the drug has been vaporized.

77. The method according to claim 50, wherein the predefined vaporization temperature is approximately 200°C to approximately 260°C.

78. The aforementioned drug is vaporized. Heating a conductive column to the predefined vaporization temperature, passing a vaporized amount of air that passes through the drug assembly above the conductive column, thereby exposing the drug to the vaporized amount of air heated to the predefined vaporization temperature, and This includes heating the drug cartridge containing the drug to the predefined vaporization temperature, The heat supplied to the drug cartridge and the heated vaporized air cause the drug to turn into vapor. The vapor then cools and condenses to form an aerosolized drug suspended in the aforementioned amount of air. The method according to claim 50, wherein the vaporized amount of air carries the aerosolized drug to the aerosol containment device.

79. The method according to claim 78, wherein the final aerosolized drug for administration to the patient is formed during further thermal condensation occurring in the aerosol containment device.

80. The method according to claim 50, wherein the predefined vaporization temperature is approximately 200°C to approximately 260°C.

81. The method according to claim 80, wherein the predefined vaporization temperature is approximately 235°C.

82. The method according to claim 78, wherein the amount of air to be vaporized is approximately 0.5 L to approximately 3 L.

83. The method according to claim 82, wherein the amount of air to be vaporized is approximately 2 liters.

84. The method according to claim 78, wherein the vaporized air is supplied at a flow rate of approximately 5 L / min to approximately 25 L / min.

85. The method according to claim 84, wherein the flow rate is approximately 7 L / min.

86. The method according to claim 50, wherein the drug has a melting point of about 50°C to about 80°C.

87. The method according to claim 50, wherein the drug has a melting point of about 67.5°C.

88. The method according to claim 51, wherein the inner surface of the holding chamber is configured to prevent the aerosolized drug from adhering to it.

89. The method according to claim 88, wherein the inner surface of the holding chamber is antistatic.

90. The method according to claim 51, wherein the inlet of the holding chamber is configured to minimize adhesion of the aerosolized drug.

91. The method according to claim 50, further comprising displaying instructions for the user on the display screen of the vaporizer.

92. The above instruction is, Before fixing the drug assembly and the aerosol containment device to the vaporizer, fix the aerosol containment device to the drug assembly, and The method according to claim 91, comprising removing only the aerosol containment device from the vaporizer and leaving the drug assembly connected to the vaporizer after the aerosolized drug generation is complete.

93. The method according to claim 51, further comprising displaying one or more indicators on the display screen of the vaporizer.

94. The method according to claim 93, wherein the one or more indicators are one or more of the following: the device is ready to proceed with preheating, preheating in progress, preheating complete, ready to begin vaporization, vaporization in progress, aerosolized drug production complete, temperature measurement, flow rate measurement, position measurement, faulty connection warning, and error.

95. The method according to claim 93, wherein one or more indicators include a notification that the predefined vaporization temperature has been reached, a notification instructing the user to confirm that the drug assembly and the aerosol containment device are attached to the vaporizer, a notification instructing the user to start vaporization, and a notification instructing that vaporization is complete and to proceed immediately with administering the drug to the patient.